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ABSTRACT
Histamine and serotonin are important neurochemicals that maintain crucial brain
functions. Both are thought to be altered in affective and neurodegenerative disorders such
as depression and Parkinson’s disease. Histamine and serotonin are thought to modulate
one another but the exact relationship remains unknown and this gap in knowledge makes
diagnosing and treating disorders involving the transmitters difficult. The Hashemi lab
studies serotonin neurochemistry to understand serotonin’s role in psychiatric disorders.
However, histamine has remained an understudied neurotransmitter due to a lack of
analytical tools. In 2015 and 2016, the Hashemi lab pioneered a novel detection method
utilizing fast-scan cyclic voltammetry (FSCV) for the real-time detection of histamine and
serotonin in vivo. Using this method, we are able to visualize the real-time modulation of
serotonin by histamine through H3 receptors. The work herein furthers our understanding
of the histaminergic system in the brain and its modulation of serotonin. First, we provided
a review of analytical methods for monitoring neurotransmitters in the brain (Chapter 2).
Then we pharmacologically challenged various aspects of the histaminergic systems of
male and female mice and show the highly conserved nature of the brain (Chapter 3). This
study also revealed that female mice may have a more tightly regulated brain histamine
system controlled by cycling hormones. Next, we investigated the synaptic transport
mechanisms of histamine and utilized a genetically modified mouse model to rule out the
contribution of the serotonin transporter towards histamine clearance (Chapter 4). After we
characterized the histamine system and its clearance mechanism, we applied histamine
vi

FSCV to a chronic stress mouse model of depression (Chapter 5). We found brain
histamine was elevated during chronic stress and inflammation; this has large implications
given the comorbidity of psychiatric disorders and chronic inflammation. Finally, we
investigated the effect of ketamine, the newly approved antidepressant and antiinflammatory compound, on histamine transmission and subsequent serotonin modulation
(Chapter 6). Collectively, this dissertation furthers our understanding of histamine and
serotonin modulation and the mechanisms governing their transmission. Novel discoveries
will provide necessary the insight to develop more efficient and targeted therapies for brain
disorders.
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CHAPTER 1
INTRODUCTION
1.1 Brain Signaling via Chemical Transmission
A major paradigm shift occurred in the late 1950s and 1960s when the
understanding of brain communication shifted from electrical signaling to chemical
signaling.1 The chemical messengers responsible for relaying signals from the brain to the
periphery would come to be known as neurotransmitters. Histamine is a bioaminergic
neurotransmitter responsible for myriad processes in both the peripheral and central
nervous systems and is capable of modulating other chemicals in the body. One key
neurotransmitter that histamine modulates is serotonin (5-hydroxytryptamine; 5-HT). The
dysregulation of both histamine and serotonin have been implicated in psychiatric and
neurodegenerative diseases like depression and Parkinson’s disease. 2-5 Understanding the
underlying chemical miscommunication is a critical component of diagnosing and
accurately treating diseases of the brain and the absence of robust tools to do so hinders
treatment advances. The Hashemi lab specializes in developing and using electrochemical
tools to understand the unique neurochemistry of histamine and serotonin in vivo in
rodents. Relative to the serotonergic system, the histaminergic system remains
understudied in the context of psychiatric and neurodegenerative diseases, especially when
studied simultaneously. The Hashemi lab optimized an electrochemical technique that
allowed for simultaneous, real-time, in vivo detection of histamine and serotonin in rodent
brains. This current work furthers our understanding of the CNS histaminergic system and
1

the implications in inflammatory states. The focus of this dissertation will be analyzing and
understanding the modulatory effects of histamine on serotonin in healthy and
inflammatory states using electroanalytical chemistry. This will be accomplished in several
chapters: 1) Reviewing analysis methods for neurotransmitters; 2) Investigating
differences between the male and female histaminergic system in the context of
pharmaceutical challenges in mice; 3) Studying the transport mechanisms of histamine in
the CNS; 4) Determining how histamine is altered in models of inflammation and
neurodegeneration; and 5) Investigating how an atypical antidepressant affects
histaminergic signaling.
1.1.1 The Histaminergic System
Histamine is a key bioamine neurotransmitter that has roles in circadian rhythm,
arousal, appetite, and inflammation.
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The enzyme L-histidine decarboxylase (HDC) is

responsible for transforming histamine’s precursor molecule, the amino acid L-histidine,
into histamine in the tuberomammillary nucleus (TMN) located in the hypothalamus. 6-7
Similar to other monoamine neurotransmitters

(i.e. serotonin, dopamine, or

norepinephrine), histamine is stored neuronally until its release, at which point it is
packaged into vesicles via the vesicular monoamine transporter protein (VMAT).10-13
Whereas serotonin, dopamine, and norepinephrine each have their own active, high-affinity
transport mechanisms (serotonin transporter, SERT; dopamine transporter, DAT;
norepinephrine transporter, NET), an analogous transport protein for histamine has not yet
been identified.14-16 Brain histamine is thought to be exclusively degraded to telemethylhistamine by the intracellular histamine N-methyltransferase enzyme.17 It can then
be further degraded into tele-methylimidazoleacetic acid via monoamine oxidase B and
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aldehyde dehydrogenase.18-19 It is worth noting that this metabolic route is only available
for central histamine; peripheral histamine undergoes its own specific degradation through
diamine oxidase.14
From the cell bodies in the TMN, histamine neurons project widely throughout the
brain and spinal cord with the densest innervations ascending to the hypothalamus. 20-21
There have been four receptors identified associated with the histaminergic system: H 1R,
H2R, H3R, and H4R, all of which belong to the rhodopsin-like family of G protein-coupled
receptors.6 Receptors H1, H2, and H3 are expressed in large amounts throughout the brain
and while there is some recent evidence for H4R mRNA expression in neuronal cells and
microglia, the science remains unsettled.6, 22-25 However, it is important that H4R are widely
expressed in mast cells which can cross the blood brain barrier (BBB).26-27
The H1 receptor is post-synaptically located and activation leads to neuronal
excitation. Arousal and feeding behavior have been linked to H 1R activation using
knockout models to visualize behavioral deficits associated with H 1 impairment.28-32
Common over-the-counter antihistamines (diphenhydramine and loratadine; brand names
Benadryl® and Claritin®, respectively) target this receptor to block H 1 activation and
signal propagation. H2R is expressed throughout the brain and localized post-synaptically
similar to H1R, but is more consistently localized with HA projections.33-34 Particularly
high expression is found in the amygdala and hippocampus where H2R deficient mice
display cognitive impairments.35 Additionally, H2R targeted therapies are commonly
prescribed for the alleviation of gastric disorders as H2R has been shown to mediate gastric
secretion.36-37 The H3 receptor, identified in 198338 and cloned in 199939, is unique in its
location and ability. It is located presynaptically on HA neurons and functions as an
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inhibitory autoreceptor controlling the release and synthesis of histamine. 40-41 H3R is also
able to exert modulatory control over other neurotransmitter systems through locations on
presynaptic terminals of serotonin42, dopamine43, norepinephrine44, glutamate45, GABA46,
and acetylcholine.47 As such, the H3 receptor rapidly became a target for various
therapeutic strategies.48-50 Animals lacking H3R show enhanced susceptibility to CNS
inflammatory disease51 and behavior abnormalities.52 H4R are the most recently identified
receptor subtype and subsequently the least understood as briefly discussed in the previous
paragraph.53 The majority of H4R expression is confirmed in the periphernal nervous
system in mast cells, basophils, and hematopoetic cells playing a critical role in the
recruitment and activation of inflammatory cells.54-55 With similar function to H3R, H4R
has also been highlighted for its therapeutic potential.56
1.1.2 Histamine’s Role in Neurodegenerative and Psychiatric Diseases
Dysfunctions of the histaminergic system have been linked to physiological and
behavioral abnormalities. In post-mortem analyses of patients diagnosed with Huntington’s
disease, a significantly lower H3 receptor density was observed in areas of the dorsal
striatum suggesting indirect impaired control of motor function neurons.57 Significant
decreases in tuberomammillary neurons and H 1 receptor binding are observed in
Alzheimer’s disease patients.58-60 H1R knockout mice show pronounced impairment of
spatial learning and memory and reduced neurogenesis.61 Decreased histamine throughout
the CNS paired with blunted neurogenesis may partially explain the cognitive decline seen
in AD patients. Parkinson’s disease (PD) patients have significantly higher histamine levels
in the brain compared to age matched controls and show alterations in histamine receptor
expression density.62-63 Similar results have been found in a rodent model of PD.64-65
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Growing evidence highlights histamine’s role in psychiatric disorders like depression and
anxiety. Histamine receptor binding was significantly less in patients with major depressive
disorder compared to age-matched controls via positron emission tomography.66 Recently,
an HDC knockout mouse revealed that chronic histamine depletion induced depressionlike phenotypes and impaired memory analyzed by the tail suspension, elevated zero maze,
and Y-maze tests.67
1.1.3 Histamine’s Role in Inflammation
Histamine is most well-known for its role in the immune system and inflammatory
state. It is a critical signaling molecule that recruits pro-inflammatory proteins and markers
to the site of a foreign body response.68 The foreign body response can range from
something as common as the immune reaction to a splinter to oxidative stress in
Parkinson’s disease. These examples highlight two distinct locations, the splinter in the
peripheral nervous system – systemic inflammation – and oxidative stress –
neuroinflammation. Systemic inflammation is marked by upregulation of microglia,
recruitment of proinflammatory cytokines and a local increase in histamine levels. 69 While
neuroinflammation produces similar chemical markers, the effect on local levels of
histamine remains unclear for several reasons. First, the brain is a unique, dynamic medium
that is analytically challenging to probe. Secondly, histamine is present in the brain at
extremely low concentrations (nM-µM), therefore, techniques must possess the selectivity
and sensitivity to capture these low concentrations. Third, histamine, itself, presents a
distinct fundamental challenge to overcome due to ‘the observer effect’ – meaning, to
measure histamine a probe must be inserted into the area of interest (eg. brain). This action
inevitably causes a disruption of tissue and cellular communication and registers a foreign
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body response. The inflammation resulting from probe insertion causes an inherent
perturbation in histamine levels in the surrounding tissue that can result in techniques
reporting varying concentrations of histamine.
1.1.4 Sex Mediated Differences in the Histaminergic System
In 2015 the National Institutes of Health (NIH) ruled that all NIH funded research
involving pre-clinical animal models must consider sex as a biological variable.70
Previously, the majority of pre-clinical research was conducted using only the male sex to
avoid complications from the female estrous cycle.71 This has led to several instances of
untranslatable research between animal models and humans.72 Estrogen is shown to be a
major regulator of eating behavior, lordosis, and anxiety through estrogen receptor alpha
and beta (ER; ER) in the ventromedial nucleus (VMN) of the hypothalamus.73-75 In the
VMN, H1R and ERα mRNA are co-expressed in histaminergic neurons.73, 76 ER is not as
strongly expressed in the VMN as ER but is expressed in the TMN where histaminergic
projections originate.77 The localization of estrogen receptors on histamine projections
highlights the potential role estrogen plays in regulating immune response. Indeed,
estrogen and progesterone have been shown to mitigate the acute inflammatory response
to lipopolysaccharide exposure.78-81 Additionally, inflammatory diseases and the
susceptibility to the occurrence of diseases are more likely in post-menopausal women than
pre-menopausal women and age matched males.82-83
1.1.5 Classical Versus Atypical Antidepressants
Since the discovery that the main therapeutic effects of early antidepressants were
due to targeting the monoaminergic systems of dopamine, norepinephrine and serotonin,
the field has remained focused on optimizing strategies to increase levels of these in the
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brain.84 Broadly, these monoamine targeting antidepressants are grouped into ‘classical’
antidepressants adhering to the monoamine hypothesis, but research drive for these classic
antidepressants has steadily weaned.85-86 At the turn of the century a revised monoamine
hypothesis was being constructed that brought the glutamatergic system to the forefront. 87
The modulatory roles that glutamate and GABA play on the monoamines is being explored
as a new potential therapeutic route for antidepressants.88 Ketamine, an NMDA receptor
antagonist, became a molecule of interest for its rapid acting antidepressant activity when
administered in subanesthetic doses.89 The exact mechanism(s) of the new rapid acting
antidepressants are still unknown and its clear they involve several complicated
biochemical pathways.90-95 As an antidepressant and anti-inflammatory, we are interested
in understanding ketamine’s effects on central histamine.
1.1.6 Motivation for this Dissertation
Given the information above, exploring the fundamental neurochemical actions of
histamine within the brain presented a unique and challenging opportunity. The Hashemi
lab is deeply focused on the chemical underpinnings of psychiatric diseases, specifically
depression, and the nexus of histamine and serotonin holds the potential of being a rich
body of information. Therefore, my work herein, focuses on furthering the community’s
understanding of the relationship between the histaminergic and serotonergic systems and
their co-modulation. As mentioned above, measuring chemicals in the brain is a great
challenge; requiring technical ability in addition to niche tools that fulfill strict criteria. An
ideal method must have the selectivity to discern between structurally and chemically
similar neurotransmitters and metabolites, high sensitivity to monitor the low extrasynaptic analyte concentrations, a high temporal resolution to capture the sub-second
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neurotransmission process, and the micro- dimensions to target specific brain regions of
interest while causing minimal disruption to the surrounding tissue in vivo. Electrochemical
methods utilizing carbon electrodes are promising for such a challenging task.
1.2 Analysis of Neurotransmitters in the Brain
The brain is a dynamic medium in a delicate homeostasis. As stated above,
monitoring the chemicals present in the brain necessitates selectivity, sensitivity, temporal,
and size requirements. Detection and quantification methods can be delineated into two
main categories: microdialysis (followed by separation and detection) and direct
electrochemical analysis, each with their respective benefits and drawbacks. For the
purposes of this dissertation, only electrochemical methods will be discussed.
Electroanalytical methods are favorable for neurochemical analyses due to the
ability to quantify species through direct oxidation and reduction. Carbon electrodes have
proven to be the most commonly used implantable electrochemical probe due to its relative
inertness, abundance, cost efficiency, wide potential window, and rich surface chemistry.9697

Specifically, carbon fiber microelectrodes (CFMs) are extensively used in the field of

monitoring neurotransmitters as they are biocompatible, stable, minimally invasive, and
have favorable electrochemical properties.98 The CFM surface is an electrochemically rich
environment covered in striations and electrostatically charged oxygen functionalities (OH, C=O, COOH/COO-) that result in an adsorptive substrate.99 Thus, the CFM is a go-to
tool for direct electrochemical analysis of neurotransmitters in vivo.
1.2.1 Electrochemical Methods Utilizing CFMs
CFMs are covered in striations that create a rich surface for electrochemical
activity. The obvious drawback of electroanalytical methods is the key criterion that an
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analyte of interest must be readily oxidizable in the given potential window of the electrode
material. Several key bioamines in the brain, dopamine, serotonin, and histamine, are in
fact oxidizable within the potential window for carbon. In the 1960s, Ralph Adams
conducted his seminal work using crudely fabricated carbon paste disc electrodes
constructed from graphite powder mixed with mineral oil packed into Teflon tubing. 100
These electrodes were used to carry out foundational electrochemical analyses of
catecholamines.101-102

Figure 1.1: A scanning electron micrograph of
a carbon fiber microelectrode.
Amperometry involves holding an electrode at a constant potential while measuring
the current from analytes undergoing oxidization at the surface. This method excels at
temporal resolution (< 1 ms) as oxidation is only limited by diffusion to the electrode
surface since potential is constant.103 Unfortunately, holding at a specific voltage oxidizes
all analytes with oxidation potentials under that voltage and, thus, amperometry suffers
from a lack of chemical specificity which is critical when probing the brain. Amperometry
at carbon disks, fibers, and microelectrode arrays has been used extensively to study the
vesicular events of single cells ex vivo.104-105 These studies aim to further the understanding
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of neurotransmission by studying vesicle fusion pore size, duration, and the amount of
contents release during an event.106-107
Chronoamperometry was developed to increase the selectivity afforded by
amperometry. Chronoamperometry uses a square wave step function between an upper and
lower potential limit. The ratio of peak oxidative current to peak reductive current is able
to yield information about the analyte identity. There is a large capacitive (non-faradiac)
current associated with potential pulse that decays rapidly, while the faradiac current
decays more slowly over time. Analyte information is obtained through the relationship of
redox current over time. This technique has been used to study psychiatric models 108,
transport kinetics109-110, and drugs of abuse.111 Despite its improvements over
amperometry, chronoamperometry is still limited in scope and selectivity.
1.2.2 Fast-Scan Cyclic Voltammetry
Pioneered by R. Mark Wightman and Julian Millar in the mid 1980s, fast-scan
cyclic voltammetry (FSCV) (originally termed fast cyclic voltammetry) emerged as a new,
selective method to monitor the release and reuptake of dopamine in vivo by direct
electrochemical means at CFMs.112-113 FSCV has become a primary technique used by
electrochemists, neuroscientists, and pharmacologists to monitor neurochemicals in the
brain. As in traditional cyclic voltammetry, FSCV uses the combination of 2 or more linear
voltammetric sweeps (eg. A → B → A) while measuring the current from redox processes
occurring at the working electrode. This set of instructions that dictates how the potential
of the working electrode is changed with respect to time is called a waveform and is the
primary source of selectivity. FSCV employs significantly faster scan rates (100s – 1000s
V s-1) than traditional cyclic voltammetry (typically <100 mV s-1) that result in a large
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capacitive current. This necessitates background subtraction to remove it. Therefore, FSCV
is only capable of recording changes in a system and reports data as a change from baseline.
In vivo, this change is typically induced through electrical, pharmacological, or optical
stimulation of neurotransmitter release.114-116
An FSCV data set is collected on a sub-second timescale. The fast scan rate results
in the potential window being traversed in <10 ms, and the application frequency of 10 Hz
allows for analytes to preconcentrate on the electrode surface at the holding potential for
>90 ms, thereby increasing sensitivity. Scanning from the resting potential to the positive
limit is called the anodic scan, where oxidation of the analyte will occur. Once the limit is
reached, the scan direction is switched, and the cathodic scan begins, during which
reduction occurs, until the negative limit is reached. The rapid switch in scan direction
results in the aforementioned large capacitive current due a phenomenon known as the
electrical double layer.117-118 Data obtained through a complete scan of the waveform is
plotted as current vs voltage to create an analyte-specific cyclic voltammogram (CV) used
for both qualitative and quantitative analysis. FSCV software collects the CVs and stacks
them in chronological order to construct a 3D plot of current vs voltage vs time. For ease
of interpretation, 3D plots are visualized from a bird’s-eye view, termed color plots, where
current is assigned a false color as seen in Figure 1.2A. Importantly, a vertical line through
the color plot provides the CV and a horizontal line will detail how current is changing
over time.
It was only recently that FSCV was expanded for the analysis of neurochemicals
other than dopamine in vivo. Serotonin detection via FSCV is very difficult due to low
extracellular concentrations and the metabolite, 5-hydroxyindoleacetic acid, is present at
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much higher concentrations and fouls the electrode surface. 119 To overcome the surface
fouling, a thin layer of Nafion, a cation exchange polymer, is electrodeposited onto the
CFM.119

Figure 1.2: Serotonin FSCV(A) Representative serotonin color plot with a
characteristic serotonin CV inset. The green event corresponds to serotonin
oxidation occurring around 0.7 V. Abstracting the vertical dashed line will
reconstitute the inset CV. (B) Concentration vs time profile for the stimulated
release and reuptake of serotonin. B is obtained by following the horizontal
dashed line in A. The light blue bar at the bottom represents the 2 s electrical
stimulation.
We measure serotonin dynamics in the CA2 region of the hippocampus by
stimulating a dense tract of nerves that innervate numerous brain regions called the medial
forebrain bundle (MFB). Figure 1.2 shows a typical data set obtained for the stimulated
release of serotonin in the CA2. Figure 1.2A is a representative serotonin color plot with
an inset CV in the right corner. Interpretation of the color plot is described in detail
elsewhere.120 Briefly, time is on the x-axis, voltage is on the y-axis, and current is
represented in false color. The green event corresponds to the oxidation of serotonin around
0.7 V. Figure 1.2B shows a typical profile of stimulated serotonin release and reuptake
over time as [5-HT] vs time. Background is collected for 5 s followed by a 2 s stimulation,
denoted by the light blue bar, resulting in the release of serotonin which reaches a
12

maximum amplitude around 7.5 s where the rate of reuptake now overtakes the rate of
release following the end of the stimulation and the curve decays to baseline as serotonin
is reuptaken into the cells.
In 2015, the Hashemi lab expanded the scope of FSCV once again by pioneering a
novel, selective waveform for the detection of histamine in vivo that scans from -0.5 V to
-0.7 V to 1.1 V to -0.5 V at 600 V s-1.121 This method is not only able to detect histamine
but also serotonin simultaneously due to the potential window encompassing both
neurotransmitters’ oxidation potentials.122 Using this technique, we showed that the
stimulated release of histamine results in the rapid inhibition of serotonin release in the
posterior hypothalamus of mice.122 Shown in Figure 1.3A is a representative color plot of
the stimulated histamine release and subsequent serotonin inhibition. The green event
corresponds to the release and reuptake of histamine and the blue/black event corresponds
to the inhibition of serotonin. What is important to reiterate here is that FSCV is
background subtracted and therefore only captures changes. The serotonin event is shown
in blue, or negative current, which is only denoting that serotonin is decreasing with respect
to its pre-stimulation levels. It is still occurring around 0.7 V, which is serotonin’s oxidation
potential for FSCV. The stimulated release of histamine is shown in green because it is
increasing with respect to its ambient concentration. Histamine FSCV uses a stimulation
of the MFB to elicit the release of neurotransmitters, albeit a different placement along the
tract to minimize serotonin release. Figure 1.3B shows the corresponding concentration vs
time plots for both histamine and serotonin together to better visualize the releaseinhibition relationship. Following stimulation (light blue bar) [histamine] increases (blue;
top trace) and returns to baseline while the inhibition of [serotonin] (red; bottom trace) can
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be seen as it reaches peak inhibition slightly after histamine’s peak release and returns to
around 20 nM. Figure 1.3C is a representative CV collected for histamine FSCV. It is
visually very different than a serotonin CV and difficult to interpret. The broad peak around
0.2-0.3 V represents HA oxidation and the inverted peak around 0.7-0.8 V represents the
serotonin oxidation (the oxidation peak is inverted due to serotonin levels decreasing with
respect to ambient levels).

Figure 1.3: Histamine fast-scan cyclic voltammetry in the mouse
posterior hypothalamus. (A) Representative histamine FSCV color plot.
The green event is stimulated histamine release (labeled ‘histamine’) and
the blue even is the subsequent inhibited serotonin (labeled ‘serotonin’).
(B) Release and inhibition vs time profiles of histamine (blue) and
serotonin (red), respectively. Stimulation is shown as the light blue bar.
(C) Characteristic histamine CV. Blue star shows the typical histamine
peak around 0.3 V and red star shows the inverted serotonin oxidation
peak around 0.7-0.8V. (D) Histamine FSCV waveform.
The development of this novel waveform that enables the monitoring of two
neurotransmitter systems simultaneously provides a tool to obtain critical information
14

about the modulatory relationship between histamine and serotonin and widens the scope
of questions we are able to ask about the brain.
1.3 Scope of the Dissertation
In this dissertation, I first provide a review of analysis methods for neurochemicals
in the brain (Chapter 2). I then use histamine FSCV to characterize the male and female
histaminergic system and their respective response to pharmaceutical challenge via
voltammetry (Chapter 3). I then further investigated the reuptake mechanisms of histamine
in male and female mice through use of a genetic mouse model (Chapter 4). After gaining
an understanding of the functionality of the histaminergic system, I apply histamine FSCV
to a model of chronic inflammation: behaviorally depressed mice (Chapter 5). Finally, I
used histamine FSCV to understand the effects of a new ‘atypical’ antidepressant on the
modulation of histamine and serotonin (Chapter 6). An outline of this dissertation is
described below:
Chapter 1: Introduction
Chapter 2: Review of methods for neurochemical analysis in the brain.
Chapter 3: This chapter describes the voltammetric investigation of the histaminergic
system. I pharmacologically challenged receptors, synthesis, packaging, and metabolism
of histamine to determine how synaptic histamine responds in male and female mice.
Additionally, I investigated histamine release throughout the estrous cycle of female mice
and sexual differences in H3R targeting drugs.
Chapter 4: This chapter builds upon previous work that investigated the transport
mechanisms of histamine. We determined SERT, NET, and OCT may all play a role in
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histamine uptake. I used a genetically altered mouse model (Met172) with a SERT that is
insensitive to certain SSRIs to rule out SERT’s contribution to histamine uptake.
Chapter 5: This chapter covers the application of histamine FSCV to an animal model of
inflammation. I analyzed the evocable histamine levels in behaviorally depressed mice
(chronic mild stress paradigm) and compared that to age matched controls.
Chapter 6: This chapter describes the response of histamine and its modulation of
serotonin in response to a new ‘atypical’ antidepressant, ketamine. Ketamine doesn’t
directly target the monoaminergic systems like traditional antidepressants (eg. SSRIs). I
found that ketamine caused a rapid and sustained inhibition of stimulated histamine release
and greatly alleviates the inhibition of serotonin levels in the posterior hypothalamus.
Chapter 7: The final chapter summarizes the conclusions of my work and highlights future
directions of research for histamine FSCV.
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CHAPTER 2
BRAIN CHEMISTRY | NEUROTRANSMITTERS 1

1

Berger, S.N.; Hashemi, P. (2019). Brain Chemistry | Neurotransmitters. In Worsfold, P.,
Poole, C., Townshend, A., Miró, M. (Eds.), Encyclopedia of Analytical Science, (3rd ed.).
vol. 1, pp 316-331, Elsevier.
Reprinted with permission from Elsevier.
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2.0 Abstract
This

chapter focuses

on analytical detection

methods

for

measuring

neurotransmitters in vivo. The discussion begins by outlining the challenges of in vivo
neurotransmitter analysis. Then, microdialysis, an in vivo sampling method, is critically
described. Subsequently, three methods of direct detection of neurotransmitters are
presented in terms of their advantages and disadvantages. Finally, future directions of
monitoring brain chemistry are prospectively explored.
2.1 Introduction
Neurotransmission is the essential mechanism via which brain cells communicate.
This process is fundamental to all aspects of brain function. Briefly, biochemical impulses
arrive at the initiating, or presynaptic, cell that cause neurotransmitter-filled vesicles to fuse
with the cell’s membrane. The neurotransmitter contents of these vesicles are then expelled
into the small gap preceding the receiving or postsynaptic cell, called the synapse. The
neurotransmitter then interacts with a postsynaptic protein (receptor), relaying the
biochemical message from the presynaptic cell via initiation of a signaling cascade. The
neurotransmitter is subsequently inactivated in the synapse either through reuptake back
into the presynaptic cell via transporter proteins and/or enzymatic catabolism directly in
the synapse. This process is fast (sub-second), the levels of transmitters are low in the
extracellular space (nanomolar) and the synaptic space is tight (nanometers). Taken
together, these characteristics immediately render an investigation of neurotransmission a
difficult analytical challenge.
Meaningful analytical measurements of neurotransmitters are highly significant,
since there is a clear gap in the understanding of the chemical underpinnings of brain
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pathophysiology. This shortcoming makes it almost impossible to accurately diagnose and
treat disorders of the brain. A clearer definition of the roles of neurotransmitters in health
and disease would greatly enhance the ability to improve diagnostic and therapeutic
approaches to the brain.
Analytical chemists have developed a suite of tools for analysis of the low
concentration of neurotransmitters within the dynamic and harsh environment of the brain.
Each method possesses inherent advantages and shortcomings. This module represents an
overview of cutting-edge analytical approaches for neurotransmitters. The discussion
begins with an outline of the analytical challenges for monitoring neurotransmitters. Two
major classes of analytical methods, microdialysis, an in vivo sampling technique, and
direct detection at microelectrodes, are highlighted in the context of their pros and cons.
While the majority of work cited focuses on in vivo analysis, we chose to include work on
single cell exocytosis. We believe there is much value in understanding fundamental
mechanisms of neurotransmitter function via these single cell models. Cutting-edge
advances in development or applications of these methods are showcased. Finally, the
future of neuro-analytical chemistry is prospectively discussed.
2.2 Analytical Challenges for Measuring Neurotransmitters
Neurotransmission occurs as a function of many simultaneous processes that
control extracellular neurotransmitter levels. To characterize the chemistry of
neurotransmission, ideally two types of measurements are necessary. First, is the ambient
extracellular neurotransmitter concentrations that depict the system at rest. Second, is the
much faster, neurotransmitter release and reuptake events that define receptor, transporter
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and catabolic activity. In the proceeding text we refer to these measurements as slow and
fast measurements.
While slow and fast chemical measurements of neurotransmitters are the targets of
analysis, there are several, chemical and non-chemical, criteria that need to be addressed
for successful neuro-analytical measurements. These criteria are discussed below.
2.2.1 Biocompatibility
Chemical measurements, for the most part, involve direct implantation of a probe
into the tissue. Implantation of foreign objects into the brain cause rapid and severe immune
responses that serve to isolate the object from surrounding tissue. 1-2 This renders
electrochemical measurements during immune attack very challenging.
Metal substrates, such as Ag and Pt, are excellent laboratory probes because they
are inert. However, these materials are not ideal for implantation into the brain because of
a robust immune response arising primarily because Ag or Pt are not readily found in
mammalian bodies.3-4
One strategy being explored to alleviate the immune response occurring from
implantation is the controlled release of therapeutic compounds through polymer coatings.
For example, the Schoenfisch lab at the University of North Carolina has been developing
methods to control the release of nitric oxide, an immune mediator, from polyurethane
coated glucose biosensors.5-7 Another approach is to utilize a fundamentally biocompatible
material, which the body does not immediately perceive as foreign. A good example of this
is carbon. Carbon has been shown to be biocompatible and maintain its measurement
capabilities over days to weeks.8 This material has been fashioned into innumerable forms,
the most popular of which in neuroanalysis are carbon fiber electrodes.9-10 Furthermore,
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carbon electrode surfaces can easily be manipulated with polymer coatings or structural
moieties (e.g. carbon nanotubes and nanotube yarns) to increase selectivity to a specific
analyte.11-15
2.2.2 Invasiveness
Damage created by insertion of a probe is a profound consideration. The distance
through which neurotransmitters relay their biochemical messages are 10s of nanometers,
thus, the measuring probe must retain its dimensions as small as possible.
Capillaries are responsible for blood transport throughout the brain and create the
blood-brain barrier via their connection with astrocytes. If the blood-brain barrier is
compromised, brain homeostasis can be severely disrupted. The intercapillary distance
dictates the size of probe that can be introduced into brain tissue without rupturing the
blood-brain barrier. This distance varies between brain regions in rodents but does not
exceed ~30 m.16-17 Intercapillary diameter is inextricably linked with the biocompatibility
of a probe, as any material large enough to compromise the blood-brain barrier will induce
an immune response. Therefore, microelectrodes with one dimension under ~30 m show
the most promising outlook to qualify as minimally invasive. When met, the criteria of
biocompatibility and minimal invasiveness allow for probes to remain in tissue for weeks
or months without evidence of gliosis.8 Currently, sample methods are not typically able
to employ < 30 m probes but the miniaturization of standard techniques like microdialysis
is actively being pursued. One of the limiting factors in the size of microdialysis probes is
the sample membranes are prefabricated. Decreasing probe size is limited by perfusate
channels and reasonable flow rate. Microfabricated silicon microdialysis probes have been
created with 70 µm x 85 µm and 45 µm x 180 µm thick sampling areas.18-19 While
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microdialysis is limited in its size, the technique is widely applicable and recently a method
has been developed to alleviate the inevitable penetration injury response. Retrodialysis
with an anti-inflammatory compound, dexamethasone, has been shown to drastically
reduce symptoms of probe damage.20
2.2.3 Temporal Resolution
To study slow vs. fast changes fundamentally different time scales are required.
Slower shifts in ambient neurotransmitter levels can be captured with measurements every
minute to 10s of minutes. However, the fast changes that correspond to transmission
necessitate sub-second temporal resolution analysis. Of the methods surveyed below,
microdialysis serves to provide information about slower ambient level shifts while fast
voltammetric methods indicate the sub-second neurochemistry of the analyte. In recent
years, however, fast voltammetric methods have been modified to provide ambient level
information.21-23
For exocytosis analysis, amperometric methods at single cells provide microsecond
temporal resolution that resolves mechanistic information about exocytotic events.24-27
2.2.4 Sensitivity and Selectivity
Chemical messengers in the brain are present at very low concentrations, typically
in the nanomolar to low micromolar range.21,

23, 28-29

Additionally, there are many

structurally and chemically similar analytes (precursors and metabolites). Thus, a high
degree of sensitivity and selectivity (i.e. the ability to discern between analytes) is
necessary for neurotransmitter analysis. For sampling methods such as microdialysis these
criteria are less of a challenge since the ability to prepare the sample ex-vivo provides many
opportunities to improve sensitivity and selectivity. With direct analysis, however, it is
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much more challenging to acquire both a high level of sensitivity and selectivity. Thus,
most direct analysis is limited to one, at most, two analytes.12, 30-33
2.3 Neurochemical Analysis Methods
For the purposes of this section, we chose to breakdown neurotransmitter analysis
into two main factions: 1) A technique based on sampling, followed by detection, namely
microdialysis and 2) direct detection at microelectrodes.
2.3.1 Microdialysis
Microdialysis utilizes a probe that is implanted into brain tissue. This is a sampling
method that uses a semi-permeable membrane to allow the selective diffusion of analytes
into a collection stream, the dialysate. Microdialysis sampling can be used to study the
effects of pharmacological agents on various endogenous systems or metabolism of the
agents themselves. The method can also be utilized for delivery of pharmaceutical agents.
Following sample collection, the dialysate is coupled to a secondary analysis system such
as liquid chromatography - mass spectrometry34-37 or biosensors.38-40 A key advantage of
microdialysis is its ability to monitor multiple analytes.
2.3.1.1 Microdialysis Probes; Mitigating Tissue Damage and Immune Response
Microdialysis probes are typically between 200 and 300 m in diameter, because
recovery rate is directly proportional to porosity and surface area.18, 41-44 These dimensions
cause significant damage to brain tissue.2, 45 This damage creates two primary issues; first,
emanating from the probe is a concentric gradient of damaged cells extending around 250
m46 and sampling from this compromised tissue confounds data.47 Secondly,
microdialysis sampling devices greatly exceed the intercapillary distance in rodent brains
(~30 µm). This means that when implanted into brain tissue, these probes damage blood
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vessels, compromise the blood-brain barrier and induce a rapid inflammatory response. As
such, profound gliosis has been observed around the microdialysis implantation site which
reduces probe stability over time and impedes analyte diffusion into the dialysate stream.20,
48-49

To improve the integrity and longevity of microdialysis measurements, researchers
have sought to a) mitigate the initial penetration damage via probe miniaturization and b)
lessen the brain’s immune response to probe implantation. We briefly discuss these two
strategies below:
a)

A good approach for reducing tissue damage caused by the microdialysis probe
is to decrease the overall size. A significant dimension is the intercapillary
diameter of ~30 µm in the mouse brain (vide supra). To this end, Kennedy and
colleagues are miniaturizing microdialysis probes. For example, a silicon
microdialysis probe (45 µm x 180 µm) was microfabricated with a nanoporous
membrane embedded onto the probe that functions as the sampling
membrane.18-19 A key disadvantage of probe miniaturization is the loss of
recovery. At flow rates of 100 nL/min, Lee et al. only observed 2-21% recovery
rates with the microfabricated silicon probe, which has been attributed to pore
blockage.18

b)

To reduce the brain’s immune reaction to implanted probes, Michael and
colleagues

have

shown

that

retrodialysis

of

an

anti-inflammatory

glucocorticoid, dexamethasone, greatly reduces glial scarring typically seen at
microdialysis probe tracks.50-51 Without dexamethasone treatment, electrically
evoked dopamine release was not observable in tissue ~100 m from probe
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implantation nor at the dialysate outflow within 4 hours of implantation.
However, following dexamethasone retrodialysis, dopamine release was
restored in surrounding tissue and in the dialysate. Additionally,
immunohistochemistry confirmed that dopamine transporters surrounding the
probe track were preserved after dexamethasone treatment.51 Furthermore,
beneficial effects were observed for up to 5 days after cessation of
dexamethasone perfusion.49
2.3.1.2 Improving the Temporal Resolution of Microdialysis
Perfusion rates through the microdialysis probe must be slow enough (typically 12 L min-1) to allow analytes to reach equilibrium with the solution inside the probe,
facilitating sufficient recovery. This slow perfusion rate is one of the factors limiting the
temporal resolution of microdialysis experiments to slower, ambient level changes, on the
order of 10s of minutes.46, 52 Increasing the perfusion rate would provide better temporal
resolution, however this strategy is a trade off with sensitivity since a faster rate of
perfusion would mean less time for analyte diffusion into the probe. Innovative solutions
to this tradeoff are discussed below.
2.3.1.2.1 Liquid Chromatography Coupled to Electrochemical Detection
Ngo et al. reported in vivo monitoring of striatal dopamine in awake-behaving rats
with under one-minute resolution via on-line liquid chromatography coupled to
electrochemical detection. To achieve this sub-minute analysis, a previous separation53 was
modified by using an 8-port, 2-loop separation setup, increasing the sample volume from
500 nL to 600 nL and decreasing HPLC flow rate from 9.0 L min-1 to 7.5 L min-1. This
higher temporal resolution allowed a detailed view of the dopaminergic response to
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pharmacological manipulation.47 In a similar progression of experiments, serotonin was
measured at 1-3 minute time resolution.52, 54-56
2.3.1.2.2 Microchip Electrophoresis
An alternative method to rapidly analyze microdialysis samples is microchip
electrophoresis.57-60 Microchip electrophoresis uses nL sample volumes and an applied
electrical potential to separate analytes in dialysate that travels a series of conduits etched
into a silicon-based wafer. Due to the small volume used and fast separation technique,
microchip electrophoresis limits the band broadening of sample plugs.61 This approach has
pushed the temporal resolution of microdialysis sampling to under 60 s62-63, reaching < 15
s.64-67 In 2008, Wang et al. reported a microfluidic device that preserved sampling
resolution via segmentation of the dialysate flow into nL droplets by introducing an
immiscible oil.68 The oil partitioned the sample stream into discrete pockets that minimized
band broadening while allowing for <15 s temporal resolution. Recently, segmented flow
has been applied to measurements of acetylcholine69 and glutamine, glutamate and gammaaminobutyric acid, simultaneously via nano-electrospray ionization mass spectrometry
with 6 second time resolution at 100 nL min-1.70
2.3.1.2.3 Enzyme Biosensing
Microdialysis has also been coupled to enzyme biosensing for rapid (30 s) analysis.
An on-line rapid sampling microdialysis method was developed and applied to clinical
microdialysate to visualize biochemical changes during patient surgery. 40, 71 In 2018, the
resolution of clinical dialysate that had been collected off-line was compared to on-line
dialysate. Samples stored at -80°C for up to 72 days showed good time alignment with
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samples collected on-line.38 A schematic of sampling from the brain to analysis by the
biosensors is shown in Fig. 1 below.

Figure 2.1: Continuous online microdialysis analysis system for bedside
monitoring using microfluidic chips containing biosensors for glucose and
lactate and a potassium ion selective electrode. (a) shows the overall setup. (b)
Raw traces from glucose (red), potassium (purple) and lactate (green) during a
computer-controlled three-point automatic calibration run. Concentrations
indicated by legend. (c) Sequential analysis of sensor performance over 12 h
27

using automatic calibration. (d) Raw data for microdialysate brain lactate
levels collected at the bedside with three automatic calibrations. The green
boxes indicate sections of clinical data and the grey boxes indicate calibrations.
Clinical data were collected from patient 2. Reproduced from Rogers, ML. et
al. J. Cereb. Blood Flow Metab. 2017, 37 (5), 1883-1895.
A method utilizing microdialysis sampling with on-line electrochemical detection
for acetylcholine monitoring was reported by Lin et al. in 2015.39 Dialysate flowed through
a bioreactor with choline oxidase and prussian blue immobilized onto iron nanoparticles.
The enzyme-catalase pair removed choline (and subsequent peroxide) present in the
dialysate thus ensuring accurate quantification of acetylcholine at the detector.
2.3.2 Direct Detection of Neurotransmitters
In the following section we outline three methods of direct neurotransmitter
analysis: enzyme biosensors, amperometry, and fast-scan cyclic voltammetry (FSCV). The
biosensor and FSCV studies included here measure in vivo neurotransmitter concentrations
while the amperometry studies investigate exocytosis at single cells ex vivo.
2.3.2.1 Biosensors
Biosensors play a powerful role in the toolbox of neuro-analytical methods as they
are capable of monitoring traditionally non-electroactive molecules. Biosensors are
chemical detection platforms that produce a quantifiable signal proportional to a specific
analyte following an enzymatic reaction at a sensor surface.
The majority of biosensors designed for neurotransmitter analysis rely on oxidation
of enzymatically generated hydrogen peroxide as a direct proxy of analyte concentration.7274

Inclusion of a size exclusion polymer is necessary to isolate the electrode surface from

interferences while still allowing hydrogen peroxide diffusion. Two commonly used
polymers

are

a

Nafion-polypyrrole

combination
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or

1,3-phenylenediamine.72-74

Microfabrication of biosensors produces microarray electrodes composed of multiple
individual sensing sites on one ceramic substrate. A microarray of four electrodes can be
isolated to create two enzyme sensors and two in situ control sensors.75
There have been many biosensors created for a myriad of substrates since their
introduction in the late 1960s76-79 Neurotransmitter biosensors utilize enzymes that are
responsible for the endogenous break down of the analyte, i.e. glutamate oxidase for the
metabolism of glutamate. These sensors often exhibit promising results in vitro but in vivo
applications of biosensors in the brain are severely limited.1,

80-81

The two primary

challenges for in vivo biosensing are a) biosensors are large (typically >300 µm) relative
to brain tissue (see above for issues with large probes and neurotransmitter measurements)
b) biosensors rely on immobilized enzymes which have poor stability. We next discuss
these issues briefly.
Biosensors are typically hundreds of microns in 2 or all 3 dimensions.82-85
Furthermore, metals like platinum (Pt) often serve as the electrode platform. Both the large
dimensions and presence of metals like Pt serve to trigger inflammation and gliosis around
the implantation site, that creates analysis limitations as described above.86 This foreign
body reaction dramatically reduces device stability. Two strategies are being explored to
decrease the probe size and reduce local inflammation. First, the Sombers lab at NC State
has been pioneering the immobilization of glucose oxidase onto carbon fiber
microelectrodes for successful in vivo glucose measurements.87 The probe that is utilized
has a substantially smaller footprint than traditional biosensors at 25 m diameter and 100
m length. These probes were further optimized to simultaneously detect glucose and
dopamine.88 Second, the Schoenfisch lab at UNC are on the forefront of increasing the
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longevity of in vivo placement of biosensors by applying nitric oxide releasing polymers.
There are analytical challenges associated with nitric oxide loading into polymers,
undesired leaching over time and controlling the release parameters of the polyurethane
coating.7, 89 Despite current working challenges, this technique has shown promising results
in swine in vivo implantation for several days.5-6
Enzymes have a small window of efficiency in which they best function. Enzyme
activity drops off exponentially when the it is not in conditions that mimic the enzyme’s
ambient environment (e.g. temperature and pH). This means pre- and postcalibrations/preparations likely denature enzymes and reduce probe activity. Moreover,
enzyme loading on the electrode is a balancing act; a high load is necessary for adequate
response. However, this comes at the expense of production of high concentrations of
metabolic products of analysis (e.g. hydrogen peroxide) that inhibit and/or denature the
enzyme. Ongoing work is to optimize this balance.90-92
2.3.2.1.1 In Vivo Measurements
As stated above, direct in vivo analysis with biosensors is limited. In the past five
years there are a handful of studies that have been successful in vivo. Measurements of
glutamate are common. In the rat cortex, studies have been carried out using a platinum
electrode array to reveal acetylcholine and kynurenic acid’s dependence on glutamate
release.73, 93 A new glutamate sensor that benefits from sensing platforms on each side of
the ceramic substrate was reported for investigating distinct areas of the brain
simultaneously.94 Glutamate release has also been monitored in the nucleus accumbens and
ventral tegmental are in rats using a commercially available glutamate oxidase coated PtIr wire, 180 m diameter.95 Malvaez et al. were able to demonstrate that glutamate release
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in the basolateral amygdala encodes outcome-specific motivation.74 Outside of glutamate,
an enzyme-linked microelectrode array was reported for the detection of adenosine in the
rat cerebral cortex.96 The effects of learned behavior and cue detection on acetylcholine
transients have been analyzed in the rat frontal cortex using a Pt electrode with immobilized
acetylcholinesterase and choline oxidase embedded on a ceramic substrate, similar in
fabrication to the glutamate sensors detailed above.97-98
2.3.2.2 Amperometry
Although the methods discussed in this module focus on the in vivo detection of
neurotransmitters, we chose to include this section on amperometric detection of single cell
vesicular events (ex vivo) because of the fundamental importance exocytotic events play in
understanding the mechanisms of neurotransmission.
Exocytosis, the process by which neurotransmitter-filled vesicles fuse with and
expel their contents out of the cell, is a primary mechanistic player in neurotransmission.
Understanding exocytosis in terms of fusion pore size, duration, and the amount of content
released during fusion is critically important to neurotransmission studies. When applied
to single cell measurements at carbon microdisc electrodes, amperometry is a unique
technique to investigate the release dynamics of exocytosis. This is because in
amperometry an electrochemical potential is applied to the electrode and held at a constant
value thus sampling frequency can be very high and time resolution can be on the order of
microseconds.
2.3.2.2.1 Electrode Platforms; Carbon Disc, Short Cylinders, & Microelectrode Arrays
Carbon discs are the most common platform on which to perform single cell
amperometry.99 These disc electrodes are fabricated by filling a glass capillary a single
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carbon fiber and then pulling the capillary apart under heat and gravity to form a carbonglass seal. To form the disc shape, the microelectrode is beveled at a 45-degree angle.
Oftentimes, to reinforce the carbon-glass seal, a small application of epoxy resin is applied
to the electrode before experimentation. Despite variations among individual carbon fibers,
it was found that factors such as charge and maximum current were independent of surface
area and remained constant for disc electrodes made with 7 m fibers.100 Surface
modification of carbon discs to increase sensitivity is ongoing.101
Although most amperometry at cells utilizes carbon discs, carbon fibers are also
employed, although they tend to be etched to decrease their size. The cylindrical shape
enables insertion into the cell to monitor intracellular chemistry. Cylinders can also be used
for vesicle impact electrochemical cytometry (VIEC).102 VIEC utilizes the immediate
interaction of vesicle and carbon surface to explore direct vesicle release processes. VIEC
has been used to model the vesicle membrane fusion and pore opening of PC12 cells103 as
well as modeling the percentage of vesicle content oxidized with respect to cell location on
the electrode surface.104
Application of similarly designed carbon microelectrode arrays of 2, 3, and 7 disc
electrodes were used to improve spatial and temporal resolution of cellular exocytosis
measurements.105 Electrode tips were spaced 7 m apart, which demonstrated the ability
to resolve simultaneous release events. Electrode crosstalk was analyzed for fast-scan
cyclic voltammetric and amperometric detection using a 7-disc microarray.106 Crosstalk
was minimal for amperometric detection because amperometric reactions occur rapidly.
By contrast, oxidative processes measured with FSCV (described below) are slower since
analysis involves redox cycling. Here, molecules can diffuse to adjacent electrodes
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permitting substantial crosstalk. A 30 m x 30 m microelectrode array with 36 2-mwidth microelectrodes was fabricated via photolithography. Cells were adhered to the
surface to spatially analyze the heterogeneity of exocytosis.107

Figure 2.2: Vesicle impact electrochemical cytometry. (A) Optical micrograph of the
experimental setup for exocytosis. Scale bar: 20 μm. Detection of exocytosis was carried
out by applying 700 mV (versus Ag/AgCl reference electrode) to the electrode. (B) Scheme
to show the different parameters for event analysis. Reprinted (adapted) with permission
from Ye, D., Gu, C., Ewing, A. ACS Chem. Neurosci. 2018, 9(12), 2941-2947. Copyright
2018 American Chemical Society.
2.3.2.2.1 Key Studies in the Mechanisms of Exocytosis
An ongoing debate on the key mechanisms of vesicular release continues to date.26
Dynamin, an enzyme involved in the late stages of endocytosis, has been shown to have
contrasting effects during exocytosis, namely being necessary in stabilizing the fusion pore
and increasing fusion duration.108 When dynamin was inhibited, a shorter release duration
and smaller pore size were observed supporting proposed the ‘kiss-and-run’ hypothesis.108
Additionally, there is evidence that inhibiting actin, a transport mediating polymer,
influences the closing mechanisms of pore fusion and results in larger pore size and
fractional release supporting the ‘kiss-and-run’ hypothesis of release.109 Alpha-synuclein,
a protein localized at nerve endings, was shown to increase fusion duration reducing ‘kiss33

and-run’ characteristics pointing towards partial release fusion dynamics as being the
normal function.110 Experimental and mathematically modeled exocytosis provided
evidence that fusion pores do not exceed ⅕ of the radius of the vesicle, strongly detracting
the notion of full fusion.111 Recently, Ye et al. showed mechanistic evidence of pore size
and fusion duration fluctuations may explain the neuroprotective and neurotoxic effects of
lidocaine.27
Evidence of full vesicle fusion has been shown to be dependent on cell membrane
tension where, amperometric and imaging data revealed that both partial release and full
fusion were found to occur.112
2.3.3 Fast-Scan Cyclic Voltammetry
FSCV at carbon fiber microelectrodes (CFMs) can directly, electrochemically
measure certain electroactive analytes with sub-second temporal resolution.
2.3.3.1 Carbon Fiber Microelectrodes
Carbon fiber microelectrodes (CFMs) are most often used when applying FSCV to
the detection of neurotransmitters for their excellent biocompatibility and electroactive
surface and their small size. Typical CFMs used in FSCV experiments are ~7 m in
diameter and range in length from 20-150 m and benefit from small sampling areas, or
‘hot spots’ of neuronal activity.
Carbon has a wide-ranging chemical reactivity that allows for numerous paths to
surface modification. Stable polymer deposition has been achieved. 11, 13 Scanning to high
positive potential limits has been shown to increase surface oxide density and adsorptive
properties113-115 and carbon nanotube deposition has increased sensitivity towards
bioamines.15, 116-117
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2.3.3.2 Scan Rate
FSCV utilizes fast scan rates (400 - 1000 V s-1) to detect fast changes in
neurotransmitters. The electrical double layer at the CFMs charges and discharges, like a
capacitor, into the electrode. At high scan rates, this ‘charging current’ is much larger in
amplitude than the Faradaic processes that define neurotransmitter redox reactions. Thus,
FSCV is background subtracted to remove the background charging or capacitive current.
As different species adsorb to the CFM, the charge and discharge profile of the double
layer capacitor changes and as such, this current cannot be subtracted out, appearing on
FSCV color plots (raw data) as narrow peaks at switching potentials. Switching peaks
cannot be easily be utilized to identify substrates since any adsorbed species on the CFM
can create a switching peak. Thus, there has been significant efforts to remove this
erroneous signal.118
2.3.3.3 Waveforms
The waveform is an integral part of FSCV analysis. A waveform is the combination
of 2 or more linear voltammetric sweeps and a set of instructions that dictates how the
potential changes with time at the electrode. Waveforms have been modified to increase
the selectivity of analyte detection based on electrostatic and electron transfer differences
between analytes. Commonly used FSCV waveforms are illustrated in Figure 2.3 below.
2.3.3.4 Ambient Neurotransmitter Measurements with FSCAV
Because FSCV is background subtracted, it is necessary to induce a change in
neurotransmitter

concentration,

this

has

been

achieved

electrically 119,

pharmacologically120, and optically.121 Thus, the baseline, or ambient level concentrations,
are unknown with FSCV recordings. This was, for decades, a key disadvantage of the
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method. A great deal of information can be garnered from ambient level neurotransmitter
measurements concentrations.

Figure 2.3: Outline of current FSCV waveforms for various species and any
modifications to the CFM.
In 2013 Atcherley et al. introduced a method to quantify the absolute concentrations
of dopamine at CFMs utilizing a FSCV-like technique that relies on waveform selectivity
and a controlled adsorption step.22 This method, fast-scan controlled-adsorption
voltammetry (FSCAV), represents a significant analytical breakthrough for the field of
voltammetric monitoring of neurotransmitters.23 Pairing FSCV and FSCAV analysis
enables a researcher to elucidate both the fast and slow chemical changes that define
neurotransmission. Briefly, a dopamine-specific waveform is applied to the electrode, but
36

at a high enough frequency (100 Hz) that dopamine adsorption to the electrode is
minimized. The waveform is then ‘switched off’ and a constant potential is applied instead
for 5-15 seconds to allow dopamine to come to an adsorption equilibrium on the electrode
surface. The dopamine waveform is then reapplied, resulting in rapid oxidation/reduction
of the adsorbed dopamine, essentially quantifying the ambient dopamine surrounding the
CFM. FSCAV was expanded to ambient serotonin measurements in 2017 by Abdalla et al.
with slight modifications to the electrode surface, specifically, electrodeposition of Nafion
prior to the experiment.21

Figure 2.4: Serotonin FSCAV (A) Representative FSCV (i) and FSCAV
(ii) color plots of 100 nM serotonin in vitro. (B) Cyclic voltammograms
extracted from the vertical dashed lines in A(i) and A(ii) after normalization
(current/maximum current). Vertical orange dashed lines represent
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integration limits. Reprinted (adapted) with permission from Abdalla, A. et
al. Anal. Chem. 2017, 89 (18), 9703-9711. Copyright 2017 American
Chemical Society.
2.3.3.5 Chronically Implanted Electrodes
Typical FSCV experiments will last 3-8 hours with an acutely implanted electrode.
Uncertainties regarding the long-term stability of and the foreign body reaction to
chronically implanted microelectrodes were eased in 2010 when the Phillips lab reported
stability and minimal tissue disruption, confirmed by immunohistochemical staining, up to
four months post-implantation of a CFM.8 Chronically implanted CFMs have also be
applied to awake-behaving studies of non-human primates with successful detection
occurring up to 100 days post-implantation.122 A key feature to highlight is the fact that
CFMs renew their surface when the applied potential is sufficiently high to oxidize carbon
(i.e. >1.1 V vs Ag/AgCl). While this method likely contributes to long term stability in
response, long-term waveform application may steadily etch the carbon electrode,
decreasing the overall size of the electrode and compromising the carbon-glass seal.115
2.3.3.6 Expanding Beyond Dopamine; Increasing the Scope of FSCV
For several decades, in vivo FSCV measurements were limited to dopamine. A serotonin
selective waveform was established in 1995123 and optimized with electrode modification
in 2009 for selective in vivo serotonin analysis in rats.11 Two factors were crucial for the
optimization of in vivo serotonin FSCV. First, a thin layer of Nafion, a cation exchange
polymer, is necessary to block the electrode fouling effects of serotonin metabolites.
Second, a high scan rate (1000 Vs-1) exploits the more favorable electron transfer kinetics
for serotonin redox reactions vs. dopamine, enabling more sensitivity towards serotonin.
In vivo serotonin FSCV has revealed evidence of dual transport mechanisms in the
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serotonin synapse and discrete circuitry dependent on sublayer morphology within the
medial prefrontal cortex.124-125

Figure 2.5: Met-enkephalin FSCV (A) Triangular waveform (TW). (B)
Modified sawhorse waveform (MSW). (C, D) Representative in vitro
voltammetric data collected using the waveforms depicted in parts A and B,
respectively, where the ordinate is the potential applied to the carbon-fiber
electrode, the abscissa is time in seconds, and the current (nA) is depicted in
false color. 2 μM M-ENK was introduced to the microelectrode at the time
indicated by the red bar. Displayed voltammograms were extracted at the
time indicated by the dashed line. Asterisks indicate electrode fouling.
Reprinted (adapted) with permission from Schmidt, AC. et al. Anal. Chem.
2014, 86 (15), 7806-7812. Copyright 2014 American Chemical Society.
Fast-scan cyclic voltammetry has been expanded to include hydrogen peroxide126127,

adenosine12,

117,

octopamine128, tyramine129, histamine130, norepinephrine131-132,

molecular oxygen133-134, methionine-enkephalin135 and most recently, melatonin.30
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Figure 2.6: Melatonin fouls the surface of the carbon-fiber microelectrode using the
traditional FSCV waveform. The traditional waveform for FSCV detection is defined
as a −0.4 V holding potential scanned to 1.3 V switching potential and back at a rate
of 400 V/s and 10 Hz frequency (A). A three-dimensional color plot represents the
change in current as a function of both voltage and time. Melatonin (5 μM) is
manually injected at approximately 5 s and washed away at approximately 10 s
(denoted by blue arrows). For the traditional waveform, a secondary oxidation
product remains even after melatonin has been flushed away by buffer. The CV for
melatonin is not stable over time (i–iv). (B) A waveform for melatonin that
eliminates fouling at the electrode surface is shown (0.2 to 1.3 V at 600 V/s). CVs
remain stable during the length of the injection (i–iii) and are not present after the
analyte was washed away (iv). Reprinted (adapted) with permission from Hensley,
AL., Colley, AR., Ross, AE. Anal. Chem. 2018, 90 (14), 8642-8650. Copyright 2018
American Chemical Society.
Another key disadvantage of FSCV is that it is traditionally limited to detection of
individual analytes. Simultaneous detection of dopamine and oxygen in anesthetized rats
was reported in the early 1990s133-134 while simultaneous dopamine and glucose detection
was recently reported.88 The approach of multi-monitoring has been applied to studies of
oxygen and dopamine changes in response to spreading depolarization. 31 In 2016
Samaranayake and colleagues published a report detailing pharmacological and
mathematical evidence of histaminergic modulation of serotonin in the mouse
hypothalamus.32 FSCV’s fast measurements captured an increase in the concentration of
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extracellular histamine coincided with a decreased release of serotonin. Evidence pointed
towards activation of H3 receptors on presynaptic serotonin terminals functioning as a
negative feedback loop to inhibit serotonin release. From this study, it is clear that
expanding the ability of FSCV to monitor multiple analytes simultaneously can resolve
questions surrounding the interaction of neurotransmitters in the synaptic area.
Appreciating the connection of neurotransmitters can be used to better design and
understand therapeutic effects of drugs.

Figure 2.7: Histamine FSCV. (ai & aii) The position of electrodes (stimulation and
carbon fiber microelectrodes) in the mouse brain. (bi & bii) Representative color
plots of the stimulated release of histamine and serotonin in the premammillary
nucleus (PM) and stimulated release of serotonin in the substantia nigra pars
reticulata (SNr), respectively. (ci & ii) Superimposed cyclic voltammograms of in
vivo and in vitro histamine and serotonin signals taken from vertical dashed lines in
the PM. (ciii) Comparison of normalized cyclic voltammograms of in vivo serotonin
signals taken from vertical dashed lines in both PM and SNr. HA, histamine; 5‐HT,
serotonin. Reprinted with permission from Samaranayake, S., et al. J. Neurochem.
2016, 138 (3), 374-383. Copyright 2016 John Wiley and Sons
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2.3.3.7 Instrumentation
FSCV instrumentation has long been sourced from prominent academic labs,
whose electronics facilities assemble systems (e.g., University of North Carolina’s UEI
potentiostat, University of Washington’s FSCV system, etc.). Limited technical and
customer support, long purchasing lead times, and significant costs involved with such
academic systems led to the emergence of commercial FSCV instrumentation options (e.g.,
Pine Research Instrumentation WaveNeuro, Pinnacle Technologies, Inc.), which have
supported growth in the area of electroanalytical neurochemistry. The Dagan Corporation
is an additional supplier of FSCV potentiostats as well.
Data analysis software is available from several commercial or academic entities.
Pinnacle Technologies, Inc. includes their FSCV software package with purchase of a
system. The HDCV software package can be purchased from UNC at Chapel Hill, the
WCCV software package can be purchased from Knowmad Technologies, LLC (Tuscon,
AZ) or the Demon Voltammetry & Analysis software suite is freely available to academics
and non-profits. (Wake Forest)
2.4 Prospects and Conclusions
Analytical neurotransmitter measurements is a thriving and cutting-edge field.
Conventional limits of microdialysis are continuing to be pushed further to allow for less
invasive, faster, more efficient sampling and separation methods. Decreasing the footprint
of microdialysis probes through microfabrication will allow for more reliable sampling
from intact tissue. With the increasing body of work demonstrating the advantages of
locally perfusing anti-inflammatory agents, the field of microdialysis sampling, as a whole,
stands to benefit from adopting this method. Along with smaller membranes, the resolution
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of microdialysis is now steadily under the one-minute mark for on-line analysis with some
methods reaching single second resolution. The trend is expected to continue with the
joining of efficient microfabricated probes and single-second on-line detection.
Recent developments in biosensor technology have explored the use of substrate
anchored aptamers for the selective detection of molecules. Aptamers are short chained
single stranded DNA or RNA that have a unique 3D conformation. They are synthetically
produced and can therefore be tailor-made for various molecules. DNA based aptamer
sensors that selectively bound to dopamine have been explored for their applications in
dopamine monitoring.136-137 Additionally, the Andrews lab at UCLA has been exploring
the use of DNA aptamer-based sensors for dopamine138 and have been expanding the
applicability by detecting glucose, serotonin and dopamine in mouse serum with tailormade field-effect transistors.139
A new class of multimodal monitoring has recently emerged as a promising method
to stimulate and monitor numerous processes simultaneously. In a 2017 Nature
Neuroscience report, Park and colleagues described a miniature device consisting of six
individual electrodes, two microfluidic channels and a fiber optic channel for
photostimulation.140 In vivo proof of concept was demonstrated by implantation in the
medial prefrontal cortex of a mouse. There, viral injections were delivered through the
device’s microfluidic channels followed by photostimulation and electrophysiology
recordings. This device demonstrated favorable chronic stability in awake-behaving mice.
Additionally, Patriarchi and colleagues introduced a novel fluorescence intensity-based
genetically encoded dopamine indicator coined “dLight1.”141 Transfection of a viral
protein into the striatum permitted two-photon imaging of dopamine response to an
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electrical stimulation and cocaine challenge in slice preparations in addition to
optogenetically stimulated dopamine release. Fluorescence data were also collected from
awake-behaving mice in response to pharmacological administration and visuomotor
learning tasks. Multimodal monitoring represents a substantial advancement in the field of
neuroanalysis and the growing field of optogenetics.
Recently a novel method has been developed, by Mei Shen’s group, to detect nonelectroactive neurotransmitters that utilizes ionic transfer across an immiscible liquidliquid interface (ITIES).142 A nanopipet filled with 1,2-dichloroethane was submerged into
an aqueous solution of acetylcholine, tyramine, and serotonin. Electrodes placed in each
phase allows the interface to function as the working electrode (WE). A voltammetric
sweep is applied to one of the electrodes that can detect ionic transfer when charged
molecules are polarized and cross the interface (WE). This method was applied to the
detection of gamma-aminobutyric acid (GABA) in aqueous solution in 2018 with slight
modification.143 Due to GABA being neutral at pH ~ 7, it required the addition of octanoic
acid in the organic phase (nanopipet filling) to facilitate transfer of GABA through the
liquid-liquid interface. Linear current increases were shown for serial additions of GABA
concentrations for a small range. However, these experiments show the exciting first steps
of a new analytical strategy to quantify non-electroactive neurotransmitters in aqueous
solutions.
Single cell amperometric recordings of exocytosis appears to be focusing on a
consensus of ‘kiss-and-run’ release as being the main or only method of release.
Investigations of proteins regulating the fusion pore size will continue to shed light on
possible reasons for impaired neurotransmission during neurodegenerative disease and
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other psychiatric disorders. Vesicle impact electrochemical cytometry and microelectrode
arrays are essential tools for investigating intracellular vesicle dynamics and heterogeneous
exocytotic events, respectively.

Figure 2.8: Newly introduced detection mechanism based on pH
modulation from an organic acid in the oil phase. This mechanism enables
the direct electrochemical detection of γ-aminobutyric acid (GABA), an
important neurotransmitter and a zwitterion, with nanoITIES pipet
electrodes. Chemical structures of GABA at pH ≈ 7 (a) and pH ≈ 3 (b). The
pKa of the amine and carboxylic acid moieties of GABA are 10.22 and 4.53,
respectively. Without organic acid modulation, GABA is not detected; in
contrast, after adding an organic acid, octanoic acid, to the oil phase
contained inside the pipet, GABA is detected (c). Reprinted (adapted) with
permission from Iwai, NT., et al. Anal. Chem. 2018, 90 (5), 3067-3072.
Copyright 2018 American Chemical Society.
FSCV continues to be a leading method for neurotransmitter analysis in the quality
and accuracy of data it delivers. The scope and quantity of analytes are continually being
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improved. Additionally, new brain regions are being explored as they are implicated in
emerging disease states. We anticipate in vivo monitoring of trace metals with FSCV in the
very near future. Trace metals, such as Cu2+, act as important cofactors in several synaptic
processes and will help create a more thorough understanding of neurotransmission. FSCV
analysis will continue to play a foundational role in determining the synaptic underpinnings
of neurotransmitter regulation.
In conclusion, a clear gap persists in understanding the fundamental chemistry of
the brain with emphasis placed on obtaining meaningful analytical measurements of
neurotransmitters. Targeted brain diagnoses and therapeutics are very difficult without
these paired measurements. Understanding the role and function of neurotransmitters in
healthy and diseased states would serve to greatly improve approaches to clinical treatment.
This module served to outline the most recent, cutting edge analytical
advancements in neurotransmitter analysis spanning primarily the last five years. There is
a rich literature of important developments and applications for monitoring molecules in
neuroscience. The discussion began with an outline of the analytical challenges
encountered when monitoring neurotransmitters. Two major classes of analytical methods,
in vivo microdialysis sampling and direct detection at microelectrodes, were highlighted
with their respective advantages and disadvantages. Cutting edge advancements,
applications and prospects of these methods were showcased.
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CHAPTER 3
VOLTAMMETRIC CHARACTERIZATION OF THE CENTRAL
NERVOUS HISTAMINERGIC SYSTEM IN MALE & FEMALE MICE1

1

Berger, SN., Hersey, M., Baumberger Altirriba, BM., Samaranayake, S., Bain, I.
Hashemi, P. Voltammetric characterization of the ventral nervous histaminergic system in
male and female mice. In preparation. J. Neurochem.
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3.0 Abstract
Histamine is an important molecule that plays a key role mediating inflammation
throughout the body. In the central nervous system (CNS), histamine has a demonstrated
ability to function as a neuromodulator. Historically, a substantial amount of
pharmacological testing was carried out using only male animal models, however, in 2015
the National Institutes of Health mandated that sex be included as a biological variable.
Histamine remains understudied in the CNS especially with respect to how the male and
female histaminergic systems respond to pharmacological treatments. In this chapter, we
first compare the male and female systems and the influence the estrous cycle has on the
histamine system under control conditions. Next, we target histamine receptors, vesicular
packaging, synthesis, and histamine metabolism to explore differences between the sexes.
We found robust similarities between male and female evoked histamine levels and no
difference throughout the estrous cycle. Additionally, we found similar responses across
sexes regarding receptors H1 and H2 antagonism, inhibition of vesicular packaging, and
inhibition of synthesis and metabolism. Our data revealed that sex should be considered
when evaluating the effectiveness of H3 targeting compounds as antagonism via
thioperamide did not elevate histamine levels above control in female mice, even when
pretreated with an H3 agonist to first decrease histamine. We posit that cycling hormones
in pre-menopausal females provide a crucial anti-inflammatory role and regulate histamine
levels in the brain as an evolutionary trait. Our study demonstrates the highly conserved
nature of neurological systems and will aid in designing therapeutic strategies for both male
and female sexes.
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3.1 Introduction
Histamine is a biological amine with a well-established role in mediating
inflammation, found in immune cells including glia1, mast cells2-3, and T-cells.4 In addition
to its roles in the immune system, histamine has also been identified as a neuromodulator. 1,
5

In the central nervous system, histamine cells bodies reside in the tuberomammillary

nucleus (TMN) with projections that innervate throughout the brain.6-8 Studies have shown
that histamine is able to modulate the release of other neurotransmitters such as serotonin,
dopamine, acetylcholine, glutamate and GABA.5 The majority of previous literature has
been based on experimentation of male animal models (typically mouse or rat) and that
data is then extrapolated to female models assumed to behave and respond in sufficiently
similar ways. In 2015, the NIH mandated that all animal-based experiments carried out
under their funding would have to consider sex as a biological variable.9 Differences in the
peripheral histamine systems of male and female mice have been shown,10-11 along with
previous suggestions that histamine may be present at higher basal levels in females. 12-14
Additionally, hypothalamic concentrations of histamine and its associated enzymes are
found to vary through the estrous cycle.15-18 However, due to the difficulties with
measuring histamine in the brain, there is a clear lack of information regarding central
histamine chemistry between the sexes and if peripheral histamine relates to central.
CNS histamine has been previously studied using brain homogenates 15, 19, in vivo
microdialysis

coupled

to

high-performance

liquid

chromatography20-21,

and

electrophysiology.22-23 More recently, the Hashemi lab developed a fast-scan cyclic
voltammetry (FSCV) method to selectively detect histamine in vivo.24-25 The power of our
technique is that it creates minimal inflammatory response and directly measures both
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histamine and serotonin at a single carbon fiber microelectrode (CFM).24 We showed that
evoked histamine resulted in an inhibition of serotonin release due to H 3 receptors present
on 5-HT terminals; this data was in agreement with previous findings.26-27
In this study we investigated potential sex differences of the central histaminergic
system between male and female. We first use FSCV to characterize the release and
reuptake characteristics of histamine release of both sexes and the effects of this release on
serotonin under control conditions. We then compared the evoked release of histamine
throughout the four stages of the mouse estrous cycle, namely estrus, metestrus, diestrus,
and proestrus. Next, an extensive pharmacological screening is undertaken to target
histamine receptors H1R, H2R, H3R, H4R, histamine synthesis, vesicular packaging, and
metabolism in both male and female mice and compare the effects of each. Interestingly,
the only significant differences we find were when targeting H3R in females, leading us to
explore the possibility of cycling hormones playing a key role in the female mouse’s ability
to mitigate immunologic signaling. Finally, we compared the release and reuptake profiles
of stimulated histamine with electrode placement in the posterior hypothalamus and found
that regions receiving significant input from hormones, (i.e. ventromedial nucleus) are
more likely to have variable profiles. This study provides broad insight into the
histaminergic system of male and female mice and will yield better understanding of how
an understudied neurochemical system functions.
3.2 Materials and Methods
Chemicals and Reagents
All chemicals were used as received from the supplier. Diphenhydramine
hydrochloride (20 mg kg-1; Sigma Aldrich, St. Louis, MO, USA), zolantidine dimaleate
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(10 mg kg-1; Tocris, Minneapolis, MN, USA), immepip dihydrobromide (5 mg kg-1; Sigma
Aldrich), thioperamide maleate (20 mg kg-1 or 50 mg kg-1; Sigma Aldrich and Tocris),
tacrine hydrochloride (2 mg kg-1; Tocris), and α-fluoromethylhistidine (20 mg kg-1;
Toronto Research Chemicals, North York, ON, CAN) were all dissolved in sterile saline
(0.9% NaCl solution, Mountainside Medical Equipment, NY, USA) at 5 mL kg-1.
Reserpine (10 mg kg-1; Sigma Aldrich) was dissolved in 0.1 % acetic acid (Sigma Aldrich)
in sterile saline at 5 mL kg-1. Tetrabenazine (Sigma Aldrich) was dissolved in 10 % DMSO
(Sigma Aldrich) in sterile saline with 1 M HCl (10 µL mL-1 injection volume). All solutions
were made fresh at the time of injection and all injections were given via intraperitoneal
(ip) injection. Urethane (Sigma Aldrich) was dissolved in sterile saline as a 25 % w/v
solution and administered at 7 µL kg-1.
Electrode Fabrication
All electrodes are made in house. A single carbon fiber is aspirated into a
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige,
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is trimmed
under light microscope to ~150 µm by scalpel. An electrical connection is forged with the
fiber through a stainless-steel connecting wire (Kauffman Engineering, Cornelius, OR,
USA) and silver epoxy. Finally, a thin layer of Nafion (LQ-1105, Ion Power, New Castle,
DE, USA) is electrodeposited onto the fiber surface at 1 V for 30 s; the coated fiber is dried
for 10 min at 70 °C.28
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Data Collection and Analysis
Fast-scan cyclic voltammetry was performed on anesthetized mice using a ChemClamp potentiostat (Dagan Corporation, Minneapolis, MN, USA), custom built hardware
interfaced with PCIe 6341 & PCI 6221 DAC/ADC cards (National Instruments, Austin,
TX), and a Pine Research headstage (Pine Research Instruments, Durham, NC, USA).
WCCV 3.06 software (Knowmad Technologies LLC, Tucson, AZ, USA) was used to
control the hardware and perform data analysis. The histamine waveform (-0.5 V to -0.7 V
to +1.1 V to -0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at 10 Hz for 10 min
prior to data collection. Data were collected at 10 Hz. Histamine was evoked via biphasic
stimulation applied through a linear constant current stimulus isolator (NL800A Neurolog,
Digitimer North America LLC, Fort Lauderdale, FL, USA) with stimulations at 60 Hz, 360
µA, 2 ms in width, and 2 s in length.
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3
kHz low pass filter). Four control evoked files, 10 min apart, were averaged for the control
evoked histamine signal after which one compound from 3.2.1 was administered and files
were collected at 0 min, 5 min, 10 min, and every 10 min thereafter until 120 min. For
immepip-thioperamide experiments, data were collected for 60 min as described followed
by administration of thioperamide immediately after the 60 min file was collected. Files
were then collected for an additional 60 min in the same fashion as described above.
Currents obtained were converted to concentrations through previously generated
calibration factors for both histamine (2.825 µM nA-1) and serotonin (11 µM nA-1).24-25 At
the completion of each experiment, a large voltage (~10 V; ~2 min) was applied to the
CFM to lesion the surrounding tissue for histological analysis. Mice were euthanized,
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brains were rapidly harvested and stored in 4% paraformaldehyde solution. Prior to
sectioning, brains were transferred to 30% sucrose solution for 24 h minimum. Brains were
rapidly frozen and sectioned into 25 µm slices (Thermo Scientific Cryotome FSE, Thermo
Scientific, Waltham, MA, USA) and visualized under light microscope to confirm
electrode placements.
Statistical Analyses
Average control response was generated from four current vs time traces per animal
and averaged to create an overall group average. To determine the t 1/2, a code was custom
written in Excel to fit the reuptake component of the curve and calculate the time taken to
reach half the maximum amplitude. Exclusion criteria were based on outliers (via Grubbs
test) and animals that did not survive the experimental paradigm. Standard error of the
mean (SEM) was calculated using the average response of each animal (n = # animals).
Significance between two points was determined by 2-tailed paired t-test and taken as p <
0.05. For non-normally distributed data (via Shapiro Wilk test), the Kruskal-Wallis H test
was used to determine significance and taken as p<0.05. All error bars represent the
standard error of the mean (SEM).
Animals and Surgical Procedure
Animal procedures and protocols were in accordance with the regulations of the
Institutional Animal Care and Use Committee (IACUC) at the University of South
Carolina, accredited through the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC). Male and female C57BL/6J mice aged 6-12 weeks
were used. Animals were group housed with ad libitum access to food and water and were
kept on a 12 h light/12 h dark cycle (lights on 0700/lights off 1900).
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Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed
induction of deep and sustained anesthesia from an intraperitoneal injection of urethane
(above). Mouse body temperature was maintained using a thermal heating pad (Braintree
Scientific, Braintree, MA, USA). All surgical coordinates were taken in reference to
bregma.29 A Nafion coated CFM was lowered into the posterior hypothalamus (AP: -2.45,
ML: 0.50, DV: -5.45 to -5.55) and a stimulating electrode (insulated stainless-steel,
diameter: 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial
forebrain bundle (AP: -1.07, ML: +1.10, DV: -5.00).24 A pseudo-Ag/AgCl reference
electrode, created by chloridizing a polished silver wire in HCl (15 s in 1 M HCl at 5 V),
was placed in the contralateral hemisphere.
For the analysis of sex and estrous cycle differences control histamine and serotonin
data were pooled. Due to the sensitivity of the measurements being made, we are unable to
determine the estrous cycle stage prior to the experiment as we have observed in previous
animals that doing so influences release and reuptake characteristics. For cycle
determination, vaginal lavage was performed following the conclusion of data collection.
Briefly, approximately 10 µL of sterile saline was administered and quickly removed from
the vagina and then visualized under low power light microscope to determine estrous cycle
stage via cytological examination.30 (Figure B1)
3.3 Results
3.3.1 Control Evoked Histamine and Serotonin Inhibition Does Not Vary Between Sexes
The stimulated histamine release and the resulting serotonin inhibition is shown in
Figure 3.1. Panel A is a representative color plot of histamine FSCV with a CV inset in
the top right corner. Averaged male stimulated histamine release (Ampmax: 7.54 ± 1.20 µM)
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and serotonin inhibition (Ampmax: 42.53 ± 4.74 nM) is shown in blue in (B). In (C), the
female stimulated histamine release (Ampmax: 7.11 ± 1.10 µM) and serotonin inhibition
(Ampmax: 45.33 ± 4.72 nM) is shown in red. Tabulated in (D) are the max amplitude values
for overall histamine peak release (Ampmax male-female: p = 0.80) and serotonin inhibition
(Ampmax male-female: p = 0.98), the ratio of peak release to peak inhibition (HA/5HT:
male: 0.19 ± 0.02; female: 0.16 ± 0.02; p = 0.34), and the rate of decay for the stimulated
histamine release (t1/2 : male: 3.1 ± 0.4 s; female: 3.9 ± 0.7 s; p=0.34). The sample size was
equal for male and female mice at n=20.

Figure 3.1: Control evoked histamine is not significantly different between male
and female mice. A) representative color plot shows the stimulated release and
reuptake of histamine as the green event and the blue event is the inhibition of
serotonin. Inset in the top right corner is the characteristic CV with peaks
occurring around 0.2 V for histamine and 0.7 V for serotonin oxidation. The
concentration vs time traces for the release of histamine and inhibition of
serotonin is shown for B) male and C) female mice. The electrical stimulation (2
s) is represented by the grey bar. D) tabulated data of release and inhibition.
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3.3.2 Control Evoked Histamine and Serotonin Inhibition Does Not Vary Throughout
the Estrous Cycle
We next evaluated the effect of estrous cycle stage on stimulated histamine release
and inhibition of serotonin. Figure 3.2A shows the stimulated histamine release throughout
estrus, metestrus, diestrus, and proestrus. We found no significant difference in the evoked
histamine amplitude (Ampmax: estrus (blue; n=23): 6.58 ± 0.55 µM; metestrus (orange;
n=16): 6.82 ± 0.74 µM; diestrus (yellow; n=10): 7.86 ± 1.33 µM; proestrus (green; n=10):
5.80 ± 1.83 µM; p = 0.84 Kruskal-Wallis H-test) or t1/2 (estrus: 3.9 ± 0.7 s; metestrus: 5.4
± 1.1 s; diestrus: 3.8 ± 0.9 s; proestrus: 4.3 ± 1.1 s; p = 0.79 Kruskal-Wallis H-test) of
reuptake curve across estrous stages. The peak serotonin inhibition is shown across cycle
stages in Figure 3.2B (Ampmax: estrus (blue; n=23): 44.70 ± 4.04 nM; metestrus (orange;
n=16): 40.76 ± 5.93 nM; diestrus (yellow; n=10): 37.04 ± 4.92 nM; proestrus (green;
n=10): 31.74 ± 5.17 nM; p = 0.27 Kruskal-Wallis H-test). These data are tabulated in Figure
3.2C.

Figure 3.2: Evoked histamine release does not significantly differ throughout
estrous. (A) Evoked histamine release and (B) serotonin inhibition for female
mice in estrous (blue, n=23), metestrus (orange, n=16), diestrus (yellow, n=10),
and proestrus (green, n=10). The shaded grey bar represents the 2 s electrical
stimulation. (C) Tabulated data covering the maximum amplitude of [histamine]
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release, t1/2 of histamine clearance, maximum inhibition of [serotonin], and the
ratio of [histamine]/[serotonin]. Data were analyzed via Kruskal-Wallis H-test.
Significance was taken as p<0.05.
We observed the occurrence of two distinct release profiles in female mice that
occurred exclusively while in estrus. Figure 3.3 shows the single (A), double (B), and
combined (C) release profiles for evoked histamine. There was not a significant difference
in the peak histamine amplitude (Ampmax: single (red; n=13): 6.70 ± 0.94 µM; double
(purple; n=10): 6.42 ± 0.47 µM; p = 0.83 unpaired t-test) or in peak serotonin inhibition
(Ampmax: single (red; n=13): 39.85 ± 5.65 nM; double (purple; n=10): 50.97 ± 5.38 µM; p
= 0.88 unpaired t-test) between the single and double release events. At the end of data
collection, a large voltage was passed through the electrode to lesion the tissue from which
our measurements are made. This allows for histological verification of the electrode
location placement. We hypothesized that the single and double release events were region
specific. We found that electrode placements anterior to the target coordinates were more
likely to result in a double peaked release. (Figure B2)

Figure 3.3: Comparison of evoked histamine and serotonin signals during estrus.
The different release profiles obtained for [histamine] vs time in female mice during
estrus are shown in (A) single release (red), (B) double release (purple), and (C) the
combined average of the single and double profiles. Maximum amplitude of
histamine release ([HA]Ampmax: single (red; n=13): 6.70 ± 0.94 µM; double (purple;
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n=10): 6.42 ± 0.47 µM; p = 0.83 unpaired t-test) and serotonin inhibition
([5HT]Ampmax: single (red; n=13): 39.85 ± 5.65 nM; double (purple; n=10): 50.97 ±
5.38 µM; p = 0.88 unpaired t-test) were not significantly different. Significant was
taken as p<0.05.
3.3.3 H1R and H2R Pharmacology
First, we investigated how the antagonism of post-synaptic receptors H1 and H2
would affect the release and reuptake of hypothalamic histamine. Figure 3.4 shows the
male and female response to diphenhydramine (DPH) (20 mg kg-1), an H1 antagonist, and
zolantidine (10 mg kg-1), an H2 antagonist. In column (A) the administered compound and
sex is given, (B) a representative color plot of histamine release and serotonin inhibition,
(C) cyclic voltammograms confirming the electrochemical identities of histamine and
serotonin, (D) concentration vs time plots of control evoked histamine release (blue) and
following drug administration (green). No significant change in evoked histamine release
was seen in male mice given DPH (Di) (n=5; Ampmax: control: 9.22 ± 3.06 µM; post-drug:
9.38 ± 2.66 µM; p = 0.83 paired t-test) or zolantidine (Diii) (n=5; Ampmax: control: 5.84 ±
0.55 µM; post-drug: 4.90 ± 0.60 µM; p = 0.33 paired t-test). Significant slowing of
histamine reuptake was obtained 50 min following administration of DPH (Di) (t1/2 :
control: 2.7 ± 0.4 s; post-drug: 7.2 ± 1.1 s; p = 0.014 paired t-test) but not following
zolantidine (Diii) (t1/2 : control: 4.2 ± 1.3 s; post-drug: 3.2 ± 1.0 s; p = 0.46 paired t-test).
In (Dii), female mice respond to DPH with a slight decrease in histamine amplitude (n=4;
Ampmax: control: 6.78 ± 0.16 µM; post-drug: 5.34 ± 0.56 µM; p = 0.077 paired t-test) and
a slowing of reuptake (t1/2 : control: 3.3 ± 0.8 s; post-drug: 12.0 ± 2.6 s; p = 0.042 paired ttest). Female response to zolantidine was similar to male with no change in histamine
amplitude (n=5; Ampmax: control: 5.40 ± 0.65 µM; post-drug: 5.45 ± 0.87 µM; p = 0.96
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paired t-test) or clearance profile (t1/2 : control: 2.7 ± 0.7 s; post-drug: 3.8 ± 1.6 s; p = 0.59
paired t-test).

Figure 3.4: Post-synaptic H1 and H2 receptor targeting highlights differential
receptor-release communication mechanisms. (A) the drug and mouse’s sex are
listed. (B) a representative color plot for each grouping of animals is shown. The
green bar represents the 2 s electrical stimulation. (C) a representative cyclic
voltammogram from each cohort of animals. The CV is obtained from the vertical
dashed line in each color plot in B. The blue shading covers the oxidation peak of
histamine and the red shading highlights the oxidation serotonin. (D) concentration
versus time traces for control (blue) and post-drug (green) evoked histamine. Traces
are obtained from the horizontal dashed lines in color plot in Bi-iv.
3.3.4 Distinctive H3R Autocontrol Between Males and Females
We established there was no difference between histamine release, serotonin
inhibition, or the ratio of HA/5HT between male and female mice in 3.3.1. We wanted to
further investigate the regulatory role of H3 receptors in male and female mice by
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administering an H3R agonist, immepip (5 mg kg-1), and an H3R antagonist, thioperamide
(20 mg kg-1).
In Figure 3.5, male (Di) and female (Dii) mice respond similarly to H3R agonism
with an overall decrease in max amplitude (male, n=5: Ampmax: control: 7.72 ± 1.55 µM;
post-drug: 4.77 ± 1.56 µM; p = 0.024; female, n=5: Ampmax: control: 6.20 ± 0.86 µM; postdrug: 3.58 ± 0.51 µM; p = 0.005) and no change in histamine clearance (male: t1/2 : control:
4.5 ± 1.7 s; post-drug: 2.9 ± 0.6 s; p = 0.4; female: t1/2 : control: 5.6 ± 1.8 s; post-drug: 5.6
± 2.6 s; p = 1 paired t-test).

Figure 3.5: H3 targeting drugs highlight distinct response of male and female mice.
(A) the drug and mouse’s sex are listed. (B) a representative color plot for each
grouping of animals is shown. The green bar represents the 2 s electrical
stimulation. (C) a representative cyclic voltammogram from each cohort of
animals. The CV is obtained from the vertical dashed line in each color plot in B.
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The blue shading covers the oxidation peak of histamine and the red shading
highlights the oxidation serotonin. (D) concentration versus time traces for control
(blue) and post-drug (green) evoked histamine. Traces are obtained from the
horizontal dashed lines in color plot in Bi-iv.
Thioperamide administration resulted in a significant increase in evoked
hypothalamic histamine in male mice (Diii) (n=5; Ampmax: control: 8.83 ± 1.35 µM; postdrug: 12.10 ± 1.75 µM; p=0.046) while trending toward a significant slowing of reuptake
(t1/2 : control: 4.5 ± 1.7 s; post-drug: 9.9 ± 2.2 s; p = 0.051). However, in the female mice,
no such change in amplitude was observed. Female mice (Div) exhibit no change in
histamine amplitude (n=5; Ampmax: control: 7.37 ± 1.40 µM; post-drug: 7.01 ± 1.65 µM;
p=0.39) or rate of reuptake (t1/2 : control: 4.2 ± 1.6 s; post-drug: 3.9 ± 1.3 s; p = 0.48)
following the same dose of thioperamide.

Figure 3.6: Thioperamide raises histamine to control levels
following immepip pretreatment. (A) FSCV [HA] vs time profiles
of evoked histamine for control (n=5, blue), 60 min following
immepip (n=5, orange), and 40 min following thioperamide after
60 min immepip (n=4, green). Error bars have been eliminated for
clarity. (B) max amplitude of evoked histamine for control (blue),
60 min immepip (orange), and 40 min following thioperamide
after initial 60 min immepip (green). Significance between two
points was taken as p < 0.05
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Given that females did not respond to 20 mg kg-1 thioperamide but did respond to
the H3 agonist, immepip, we hypothesized there was a threshold level of extracellular
histamine that female mice were unable to surpass. Therefore, we administered immepip
(5 mg kg-1) for 60 min to decrease evoked histamine and then administered thioperamide
(20 mg kg-1) to determine if histamine levels would increase to control or exceed control
levels. Figure 3.6A shows the [HA] vs time profiles of control (blue), 60 min post-immepip
(orange), and 40 min post-thioperamide (green). Error bars have been omitted for clarity.
Following a significant decrease from immepip (vida supre), we show that thioperamide
elevates stimulated histamine only to around control level (Ampmax: immepip: 3.58 ± 0.51
µM; post-immepip-thioperamide: 5.89 ± 1.13 µM; p=0.13); we were unable to increase
evoked histamine in female mice to above control (Ampmax: control: 6.20 ± 0.86 µM; postimmepip-thioperamide: 5.89 ± 1.13 µM; p=0.83 paired t-test).
3.3.5 Histamine is Packaged via the Vesicular Monoamine Transporter
We investigated the packaging mechanisms of histamine in the brain using two
vesicular monoamine transporter (VMAT) inhibitors with different affinities for VMAT1
and VMAT2 (tetrabenazine (TBZ): 10 mg kg-1; reserpine: 10 mg kg-1). Each compound
functions by inhibiting packaging of histamine (and other neurochemicals) into vesicles
prior to exocytosis which results in the intracellular neurochemicals being enzymatically
metabolized in the cytosol. Both reserpine and tetrabenazine required modification to the
saline vehicle to fully dissolve the compounds. Reserpine was dissolved in 0.1 % AcOH in
saline and tetrabenazine required 10% DMSO in saline with 1 M HCl (10 µL mL-1).
Vehicle solutions were administered (5 mL kg-1) to each mouse for 30 min between control
files and drug files to determine any vehicle effects on the evoked histamine and serotonin
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profiles. Vehicle injections did not significantly change the evoked release in males or
females; however, female mice did have a more obvious change in release amplitude
following vehicle.
Reserpine vehicle (0.1% AcOH in saline) injection did not significantly change
histamine amplitude from control (male, n=5: Ampmax: control: 5.41 ± 1.01 µM; AcOH
vehicle: 5.43 ± 0.64 µM; p=0.98) (female, n=5: Ampmax: control: 9.17 ± 1.22 µM; AcOH
vehicle: 7.76 ± 1.01 µM; p=0.053). However, 60 min following reserpine injection, a
significant decrease in evoked histamine amplitude was observed in both male (Figure 3.7
Di) (Ampmax: AcOH vehicle: 5.43 ± 0.64 µM; reserpine: 2.72 ± 0.47 µM; p=0.009) and
female (Figure 3.7 Dii) mice (Ampmax: AcOH vehicle: 9.17 ± 1.22 µM; reserpine: 6.53 ±
1.01 µM; p=0.016). There was no change in the rate of reuptake of histamine for either sex
(male: t1/2 : control: 2.4 ± 0.7 s; reserpine: 2.8 ± 0.7 s; p=0.51) (female: t1/2 : control: 6.3 ±
2.5 s; reserpine: 4.4 ± 1.6 s; p=0.23).
Tetrabenazine vehicle (acidified 10% DMSO) administration did not significantly
change control evoked histamine (male, n=5: Ampmax: control: 7.51 ± 1.32 µM; DMSO:
7.08 ± 1.42 µM; p=0.18) (female, n=5: Ampmax: control: 9.02 ± 1.45 µM; DMSO: 7.56 ±
0.75 µM; p=0.27). After the mice received TBZ, a significant decrease in evoked histamine
was observed for both sexes (male: Ampmax: DMSO: 7.08 ± 1.42 µM; TBZ: 5.49 ± 1.44
µM; p=0.023) (female: Ampmax: DMSO: 7.56 ± 075 µM; TBZ: 3.83 ± 0.40 µM; p=0.008)
3.3.6 Pharmacological Manipulation of Histamine Synthesis and Metabolism
Finally, we targeted the beginning and end of histamine’s metabolic life cycle in
the central nervous system. We used tacrine, an N-methyltransferase inhibitor, and αfluoromethylhistidine, an L-histidine decarboxylase inhibitor, to accomplish this.
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Figure 3.7: VMAT inhibition lowers evoked histamine release. (A) the drug and
mouse’s sex are listed. (B) a representative color plot for each grouping of animals
is shown. The green bar represents the 2 s electrical stimulation. (C) a
representative cyclic voltammogram from each cohort of animals. The CV is
obtained from the vertical dashed line in each color plot in B. The blue shading
covers the oxidation peak of histamine and the red shading highlights the oxidation
serotonin. D) concentration versus time traces for control (blue) and post-drug
(green) evoked histamine. Traces are obtained from the horizontal dashed line
‘histamine’ in color plots in Bi-iv.
Administration of tacrine to male mice (Figure 3.8 Di) resulted in no change in histamine
amplitude (n=5, Ampmax: control: 9.56 ± 0.89 µM; tacrine: 9.41 ± 1.22 µM; p=0.92) and a
slowed clearance of histamine from the extracellular space (t1/2 : control: 2.8 ± 0.8 s;
tacrine: 6.0 ± 0.7 s; p=0.025). Female mice (Figure 3.8 Dii) displayed no amplitude change
following tacrine (n=4, Ampmax: control: 7.01 ± 1.79 µM; tacrine: 7.74 ± 1.85 µM; p=0.22)
and had a slowing of reuptake that trended towards a significant change (t1/2 : control: 4.8
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± 1.4 s; tacrine: 4.9 ± 2.4 s; p=0.095). It’s clear that in both male and female mice, inhibiting
the intracellular metabolic enzyme results in no change in overall release of histamine but
does cause histamine to remain in the synapse for a prolonged amount of time due to the
concentration gradient created intracellularly.

Figure 3.8: Inhibition of histidine decarboxylase lowers evoked histamine release
while inhibiting histamine N-methyltransferase results in histamine remaining in
the extracellular space. (A) the drug and mouse’s sex are listed. (B) a representative
color plot for each grouping of animals is shown. The green bar represents the 2 s
electrical stimulation. (C) a representative cyclic voltammogram from each cohort
of animals. The CV is obtained from the vertical dashed line in each color plot in
B. The blue shading covers the oxidation peak of histamine and the red shading
highlights the oxidation serotonin. (D) concentration versus time traces for control
(blue) and post-drug (green) evoked histamine. Traces are obtained from the
horizontal dashed line ‘histamine’ in color plots in Bi-iv.
Due to the limited amount of FMH we had available, we combined the male and
female responses into one grouping. We have shown that 60 min following inhibition of
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histamine synthesis via FMH, a significant decrease in stimulated histamine was observed
(Figure 3.8 Diii/iv) (n=2 male, 2 female; Ampmax: control: 8.59 ± 1.86 µM; post-FMH:
5.83 ± 1.24 µM; p=0.038). There was no change in histamine clearance ((t1/2: control: 2.4
± 0.2 s; FMH: 2.3 ± 0.4 s; p=0.82)
3.4 Discussion
3.4.1 Histamine FSCV in male and female mice
The exclusion of females from pharmacological testing can have serious
consequences for the health and safety of patients.31 Estrogen has been shown to be an
important regulator in the ventromedial nucleus (VMN) of the hypothalamus.23, 32-33 H1R
and estrogen receptor alpha (ERα) mRNA are co-expressed in histaminergic neurons23, 34
and ERβ are expressed in the TMN.35 The localization of estrogen receptors on histamine
projections highlights the potential role estrogen plays in regulating immune response.
Indeed, estrogen and progesterone have been shown to mitigate the acute inflammatory
response to lipopolysaccharide exposure.36-39 Additionally, inflammatory diseases and the
susceptibility to the occurrence of diseases are more likely in post-menopausal women than
pre-menopausal women and age matched males.40-41
In this study we set out to investigate the machinery of the central histaminergic
systems of male and female mice via response to various pharmaceutical challenges. Under
control conditions, we did not find any differences in the release of hypothalamic histamine
in male and female mice (Figure 3.1). This finding is in agreement with our previous work
that compared hippocampal serotonin between sexes and found no statistical differences. 42
Our results differed from some literature reports that suggested histamine turnover and
histamine cerebrospinal fluid concentration are higher in females43 or show lowered
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histamine in females.22 FSCV is accompanied by a large aphysiological stimulation which
releases a substantial amount of neurochemicals and is a fundamentally different type of
measurement than other sampling techniques. In vivo measurements keep brain circuits
intact and are often different than data obtained from ex vivo brain slices.44 Our data are
unnormalized and highlight the high level of conservation in neurochemical regulatory
mechanisms across individual mice.
There is an intrinsic belief that there may be neurochemical differences between
the different stages of the estrous cycle that has limited the use of females in research. 45
Due to histamine’s potential role in neuroinflammation, this belief may be even stronger;
the extent of immune reactivity has been thought to depend on the different stages of the
estrous cycle.46-47 Therefore, we compared evoked histamine in female mice during
different stages of the estrous cycle and found that histamine was not significantly different
throughout (Figure 3.2). This finding is not surprising given our prior experience with
measuring neurotransmitters with FSCV where we have had to employ aggressive means
to affect a significant but small change from homeostasis 24, 42, such as high doses of SSRIs
which correspond to profound behavioral alterations.48 Interestingly, we observed a double
release event that occurred during the estrus stage of the female cycle. We have previously
observed a similar phenomenon in the prefrontal cortex (pFC) regarding stimulated
serotonin release.49 West et al determined that the occurrence of a single release or double
release was dependent upon the specific region of the pFC the CFM was located. We
applied that assumption to the posterior hypothalamus as well and found that double peaks
were most likely to occur when the CFM was located anterior to our target coordinates.
The ventromedial nucleus, periventricular nucleus, and dorsomedial nucleus are located in
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this area and known to have a very high level of hormonal regulation.50-52 Neuronal mRNA
sampled from VMN neurons showed colocalized expression of ERα and H 1, H2, and H3
receptors.23 Indeed the regulation of lordosis has been shown to be dependent on the
interplay of histaminergic neurons and estrogens through histamine and estrogen
receptors.23, 34, 53
We conduct our histamine measurements in a specifically targeted region of the
posterior hypothalamus where we are able to detect both evoked histamine and the resulting
inhibition of serotonin. This has been shown to be an H3R mediated process by our lab and
others.1, 24, 26-27 After confirming no statistical differences in evoked histamine between
male and female mice and throughout the estrous cycle, we analyzed the level of serotonin
inhibition resulting from histamine release in the same mice. Unsurprisingly, the overall
amount of serotonin inhibition is not different between males and females, and the ratio of
maximum release to peak inhibition does not differ (Figure 3.2). Throughout the estrous
cycle serotonin did not vary significantly but a relative trend can be seen between histamine
and serotonin amplitudes across cycle stages. As histamine exhibited two release profiles,
we also compared the corresponding serotonin data of single and double events. A double
peaked histamine release resulted in a larger amount of inhibition, but the difference was
not significant (Figure 3.3). These results highlight the highly conserved nature of both
the histamine and serotonin systems to maintain a homeostatic balance in the brain.
3.4.2 Histamine receptor pharmacology in male and female mice
After determining the evoked release of histamine was conserved between male
and female mice, we wanted to explore how different receptor targeting compounds
affected the release and reuptake of histamine. Antihistamines are compounds most
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commonly prescribed for common allergies and target post-synaptic H1 or H2 receptors.
First generation antihistamines, like diphenhydramine, readily cross the blood brain barrier
and block the H1 receptor. Histamine is unable to activate the receptor to propagate
signaling resulting in the common side effect of drowsiness. In both male and female mice,
when H1 activation is inhibited, a slowing of histamine clearance is observed, presumably
to allow histamine to remain in the synapse and activate the receptor after which it would
then be reuptaken. Interestingly, these results point to a communication between H 1 and
membrane transport proteins.54 The results of zolantidine administration were unexpected
given how H1 antagonism effected reuptake. Even as a brain penetrating potent H 2
antagonist, zolantidine did not cause any significant changes in the release and reuptake
profile of histamine in male or female mice (Figure 3.4). This could be due to the
difference between diphenhydramine being an inverse agonist and zolantidine being an
antagonist.55 H2 receptors are widely expressed throughout the hypothalamus just as H 1
receptors but reuptake signaling mechanisms appear not to be linked to H2 activation and
propagation.
There is a substantial amount of literature documenting the neuromodulatory role
and autoregulatory role of the H3 receptor.1, 5, 26-27 We previously used the H3R antagonist
thioperamide when developing histamine FSCV24-25 and anticipated seeing robust changes
in brain histamine when targeting H3R. However, when an equivalent dose of thioperamide
was administered to female mice, a robust increase in histamine release did not occur. This
contrasts with previous work that observed behavior following thioperamide treatment and
found similar effects in and male female rats.56 After confirming there was consistently no
change in female mice, we hypothesized that H3R expression in females possibly is lower
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and administering a higher dose (50 mg kg-1) would test this notion. The higher dose did
not result in a similar elevated release as in male mice and we ruled out receptor expression.
We then tested whether immepip, an H3R agonist, would have a differential response in
male and female mice. We found that H3R agonism resulted in an overall decrease in
evoked histamine in both male and female mice without affecting the clearance slope
(Figure 3.4). We hypothesized potential evolutionary regulatory mechanisms are present
in female mice that do not allow histamine to elevate above a certain threshold. Ferretti et
al. suggested that stressor-induced increases in histamine release may be lower in females
than it is in males.22 Therefore, we tested this hypothesis by pretreating female mice with
immepip to cause a significant decrease in evoked histamine. Following immepip,
administration of thioperamide (20 mg kg-1) should now increase histamine to control or
above control levels. In Figure 3.5, following a significant decrease in evoked histamine,
thioperamide was only able to increase histamine back to near control levels, supporting
our hypothesis that there are intrinsic mechanisms present in the female immune system
that strictly regulate the levels of histamine in the brain. This increased control may have
evolutionary underpinnings as it is often thought that female animals exhibit more
homeostatic control and that female hormones, estrogens and progesterones, have
neuroprotective functions.57-58
Studies have shown that females experience an increased risk of developing
inflammatory disorders later in life, particularly post-menopause.40-41 Therefore we wanted
to test whether age or circulating hormone levels could influence the female response to
thioperamide. There are three potential strategies we identified. 1) perform voltammetry
experiments on mice that are undergoing or have undergone menopause (age 9-12+
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months).59 2) chemically or physically eliminate ovaries through ovotoxin administration
or ovariectomy. 3) eliminate the influence of estrogens on the immune response through
pretreatment with an aromatase inhibitor, letrozole. By pretreating female mice with
letrozole and then administering thioperamide, we would be able to view how the female
histaminergic system responds to H3R antagonism in the absence of estrogenic regulation.
This is the focus of future experiments.
3.4.3 Vesicular packaging of histamine in male and female mice
Vesicular packaging is a crucial step for monoamine neurotransmission and
disruptions can have downstream effects. Brain histamine can originate from neurons, glia,
and mast cell degranulation.5 We targeted VMAT2 with two compounds, tetrabenazine and
reserpine and examined their effect on histamine release. Tetrabenazine is selective for
VMAT2, while reserpine has affinity for both VMAT1 and VMAT2. However, VMAT2
is responsible for packaging in neurons, while VMAT1 is exclusively located in endocrine
cells.60 Additionally, Erickson et al. demonstrated that histamine displayed a 30-fold higher
affinity for VMAT2 over VMAT1 and reserpine had about 3x affinity for VMAT2 over
VMAT1.61 Both reserpine and tetrabenazine caused significant decreases in overall evoked
histamine in males and females, with females responding the strongest to tetrabenazine
(Figure 3.6 Div). This could also be due to the initially high control signals obtained in
that cohort of mice which makes the decrease appear more robust. We also confirmed that
the majority of evoked histamine was neuronal or glia based and most likely not related to
mast cell degranulation. This confirmed that histamine has similar prerelease mechanisms
to other common neurotransmitters such as dopamine and serotonin and will better help
understand the altered mechanisms during inflammatory states.
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3.4.4 Influence of Enzyme Inhibition on Evoked Histamine
We tested how inhibiting histamine synthesis might affect evocable histamine.
Other groups have used FMH to successfully lower histamine and our data are in good
agreement with those reports.62-64 Although the goal of this work was to highlight the male
and female response to compounds separately, we combined the sexes’ responses in the
case of FMH (20 mg kg-1) due to the limited amount of the compound available. Despite
the inhibition of synthesis, there still is evocable histamine 60 min after ip injection, most
likely due to the large aphysiological nature of our electrical stimulation. CNS histamine
is metabolized exclusively by HA N-methyltransferase which is located intracellularly. By
blocking the enzyme, a concentration gradient is created between the intra- and
extracellular space and histamine spends a prolonged time in the synapse. The male and
female mice responded similarly both having significant slowing of reuptake following
tacrine (ip; 2 mg kg-1) (Figure 3.7 Diii, iv). Tacrine has additional affinity for blocking
acetylcholine esterase which has been explored for cognitive boosting abilities in
Alzheimer’s patients.65-66 Our data show that the metabolic pathway of histamine,
including synthesizing and degrading enzymes, is highly conserved between male and
female mice.
What we are currently working towards is using this collection of novel
simultaneous histamine and serotonin data to create a mathematical model of the synapse.
We have made progress on the serotonin system49, 67 and have investigated parts of the
histamine system24, 68 but have not fully elucidated the mechanisms regulating the synapse
outside of standard H3R mediated inhibition.24 A model built using these data will capture
how changes in histamine receptor functionality, vesicular packaging, and synthesis and
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metabolism can affect the transmission of histamine and serotonin, a critical step in
understanding the differences between healthy and inflamed immune systems.
3.5 Conclusion
In this study, we investigated the pharmacological response of the male and female
histamine system in the brain. We compared control evoked histamine between male and
female mice and found no differences between them as well as no influence from the
estrous cycle on histamine release. We targeted histamine receptors H1, H2, H3, and H4,
vesicular packaging, synthesis, and metabolism. We found that the histaminergic system is
highly conserved between the sexes but females appear to have a stronger regulatory
control over increased histamine levels mediated through H3R. Our data highlight the
importance of considering biological sex as a variable when evaluating pharmacology data
and that simple extrapolation from male animal models to female should no longer occur.
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CHAPTER 4
INVESTIGATING HISTAMINE INACTIVATION USING THE MET172
MOUSE MODEL1

1

Berger, SN. Hersey, M., Samaranayake, S., Best, J., Nijhout, HF., Reed, MC., Blakely,
RD., Hashemi, P. Investigating histamine inactivation using the Met172 mouse model. In
preparation. Euro. J. Neurosci.
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4.0 Abstract
Histamine is an important mediator of inflammation and immune response in the
peripheral nervous system. Much less is known about histamine’s functions within the
brain and central nervous system. Only one metabolic pathway is available for histamine
within the brain through the intracellularly located histamine N-methyltransferase, despite
there not being a dedicated transport protein for histamine identified. Stimulated histamine
exhibits similar release and reuptake kinetics to that of common monoamine systems, thus,
we investigated which transporters are responsible for the reuptake of histamine in the
brain. We screened six agents to inhibit the serotonin transporter (SERT), norepinephrine
transporter (NET), dopamine transporter (DAT), and organic cation transporter (OCT) and
found compounds showing appreciable slowing of histamine clearance all have
antidepressant activity. We focused on the role of SERT inhibition towards histamine
clearance by utilizing a transgenic mouse model, the SERT Met172, which is insensitive
to certain selective serotonin reuptake inhibitors (SSRI). The SSRI escitalopram
significantly slowed histamine clearance in Met172 mice absent SERT antagonism. Our
data rule out SERT’s contribution toward histamine reuptake and are in agreement with
previous reports that propose OCT as the main transporter responsible for clearance. Our
study highlighted key off-target mechanisms of antidepressants and the need to better
understand the full spectrum of the mechanisms of these agents to improve their clinical
efficacy.
4.1 Introduction
Histamine is an important monoamine in the central nervous system (CNS) and
dysregulation can lead to behavioral abnormalities.1-4 Therapies targeting the histaminergic
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system are much less robust than other more common monoamine strategies and have
failed to reach clinical relevance for neurological disorders.3,

5-6

There is a wide gap

between understanding histamine’s roles in the CNS and developing successful therapies
because histamine’s role and its interaction with other neurotransmitter systems remain
understudied. Histamine controls monoamine release through H3 receptors on presynaptic
terminals but understanding this regulation in the context of CNS disorders is unclear.7-12
In the CNS, histamine is exclusively metabolized to tele-methylhistamine through
histamine N-methyltransferase.13 This metabolic route is only available for central
histamine; peripheral histamine undergoes its own specific degradation pathway.14 There
is evidence for partial histamine uptake into astrocytes 15 and synaptosomes16, but a
dedicated histamine transporter has not yet been identified. Previous work from the
Hashemi lab reported that the reuptake curve of histamine, as measured by FSCV, was best
fit with first order Michaelis-Menten kinetics17 similar to dopamine and serotonin that have
dedicated membrane transporters.18-19 Therefore, we sought to establish which mechanisms
might be responsible for this (suggestively) active reuptake of histamine in vivo.
Previous work from Lyn Daws’ lab has shown that the monoamine transporters
(dopamine transporter (DAT), norepinephrine transporter (NET), serotonin transporter
(SERT)) are not particularly selective for their dedicated substrate and regularly will
reuptake one another’s substrates; a phenomenon she coined ‘promiscuous reuptake.’20
Additionally, there is evidence that the non-specific membrane bound organic cation
transporter (OCT2/3) and plasma membrane bound transporter (PMAT) play a significant
role in histamine reuptake.21-22
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In this work, we inhibited SERTs (with three separate agents), DATs, NETs, and
OCTs and found that all agents, with the exception of the DAT inhibitor, slowed the
reuptake of histamine. In agreement with previous findings, OCT inhibition resulted in the
strongest inhibition of histamine reuptake.21-23 However, due to promiscuous reuptake, our
results do not definitively identify which transporter is responsible for histamine uptake.
To hone in better on the reuptake mechanism involved, we utilized a transgenic mouse
model, the SERT Met172, generated by Randy Blakely at Florida Atlantic University. In
Met172 mice, the SERT protein coding has a single amino acid substitution (isoleucine172
methionine172) that renders these mice insensitive to several SSRIs including
escitalopram, which was included in the initial reuptake screening.24 Importantly, this
substitution does not affect the function of the SERT.25 We found that administration of
escitalopram to both Met172 and wild-type (WT) mice results in the inhibition of histamine
reuptake, despite escitalopram not inhibiting the SERT, suggesting that SERTs do not play
a major role in histamine reuptake. These results suggest that there exists an active reuptake
mechanism for histamine, primarily through OCTs and negligible uptake through SERTs.
This information is critical for improving the efficacy of CNS targeting pharmaceuticals.
4.2 Materials and Methods
Chemicals and Reagents
Escitalopram oxalate (Sigma Aldrich, St. Louis, MO, USA) at 10 mg kg-1 , GBR
12909 (Sigma Aldrich) at 15 mg kg-1, desipramine hydrochloride (Sigma Aldrich) at 15
mg kg-1, citalopram hydrobromide (Sigma Aldrich) at 5 mg kg-1, sertraline hydrochloride
(Sigma Aldrich) at 10 mg kg-1, and decynium-22 (Sigma Aldrich) at 0.1 mg kg-1 were
individually dissolved in sterile saline (0.9% NaCl solution, Hospira, Lake Forest, IL,
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USA) and administered via intraperitoneal (ip) injection at a volume of 5 mL kg-1 body
weight. Urethane (Sigma Aldrich, St. Louis, MO, USA) was dissolved in sterile saline at
25% w/v and administered ip at 7 µL/g mouse body weight for surgical anesthesia.
Electrode Fabrication
All electrodes are made in house. A single carbon fiber is aspirated into a
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige,
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is then
trimmed under light microscope to ~150 µm by scalpel. An electrical connection is forged
with the fiber through a stainless-steel connecting wire and silver epoxy. Finally, a thin
layer of Nafion (LQ-1105, Ion Power, New Castle, DE, USA) is electrodeposited onto the
fiber surface at 1 V for 30 s; the coated fiber is dried for 10 min at 70 °C.26
Data Collection and Analysis
Fast-scan cyclic voltammetry was performed on anesthetized mice using a Dagan
potentiostat (Dagan Corp., Minneapolis, MN, USA) and custom built hardware interfaced
with PCIe 6341 & PCI 6221 DAC/ADC cards (National Instruments, Austin, TX) and a
Pine Research headstage (Pine Research Instruments, Durham, NC, USA). WCCV 3.06
software (Knowmad Technologies LLC, Tucson, AZ, USA) was used to control the
hardware and perform data analysis. The histamine waveform (-0.5 V to -0.7 V to +1.1 V
to -0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at 10 Hz for min prior to data
collection. Data were collected at 10 Hz. Histamine was evoked via biphasic stimulation
applied through a linear constant current stimulus isolator (NL800A Neurolog, Digitimer
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North America LLC, Fort Lauderdale, FL, USA) with stimulations at 60 Hz, 360 µA, 2 ms
in width, and 2 s in length.
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3
kHz low pass filter). Four control evoked files, 10 min apart, were averaged for the control
evoked histamine signal after which drug was administered and files were collected at 0
min, 5 min, 10 min, and every 10 min thereafter until 120 min. Currents obtained were
converted to concentrations through previously generated calibration factors for both
histamine (2.825 µM nA-1) and serotonin (11 µM nA-1).17, 27 Mathematical modeling was
via a previous model for histamine cells in MatLab.28
Statistical Analyses
Average control response was generated from four current vs time traces per animal
and averaged to create an overall group average. Exclusion criteria were based on outliers
(via Grubbs test) and animals that did not survive the experimental paradigm. Standard
error of the mean (SEM) was calculated using the average response of each animal (n = #
animals). Significance between two points was determined by student’s t-test and taken as
p < 0.05. All error bars represent the standard error of the mean (SEM).
Animals and Surgical Procedure
Animal procedures and protocols were in accordance with the regulations of the
Institutional Animal Care and Use Committee (IACUC) at the University of South
Carolina, accredited through the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC). Male and female SERT Met 172 knock in mice on
a 129S6/S4 background were backcrossed with C57BL/6J mice and wild type mice (WT;
C57 mice with 129 wildtype SERT gene (Ile172)) aged 6-20 weeks were used. Animals
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were group housed with ad libitum access to food and water and were kept on a 12 h
light/12 h dark cycle (lights on 0700/lights off 1900).
Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed
induction of deep and sustained anesthesia from an intraperitoneal injection of urethane.
Mouse body temperature was maintained using a thermal heating pad (Braintree Scientific,
Braintree, MA, USA). All surgical coordinates were taken in reference to bregma. 29 A
Nafion coated CFM was lowered into the posterior hypothalamus (AP: -2.45, ML: 0.50,
DV: -5.45 to -5.55) and a stimulating electrode (insulated stainless-steel, diameter: 0.2 mm,
untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial forebrain bundle
(AP: -1.07, ML: +1.10, DV: -5.00).27 A pseudo-Ag/AgCl reference electrode, created by
chloridizing a polished silver wire in HCl (15 s in 1 M HCl at 5 V), was placed in the
contralateral hemisphere.
4.3 Results
To screen potential monoamine transporters responsible for histamine reuptake, we
tested the effects of monoamine transport inhibitors on histamine reuptake. In Figure 4.1,
we measured evoked histamine (control, blue) and then pharmacologically inhibited the
following transporter proteins (post-drug, green): dopamine transporters (DATs), serotonin
transporters (SERTs), and norepinephrine transporters (NETs) with the following agents
(ip; n = 5 each): GBR 12909 (DAT inhibitor, 15 mg kg-1), escitalopram (SERT inhibitor,
10 mg kg-1), citalopram (SERT inhibitor, 5 mg kg-1), sertraline (SERT inhibitor, 10 mg kg1),

and desipramine (NET inhibitor, 15 mg kg-1). We found that in all cases except for DAT

inhibition, there was slowing of the rate of histamine reuptake that peaked at 60 min. The
ability of both SERT and NET inhibitors to slow histamine clearance suggests a less
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selective transporter might be involved. We therefore turned towards organic cation
transporters (OCTs) and plasma membrane monoamine transporters (PMATs) which were
inhibited with decynium-22 (OCT and PMAT inhibitor, 0.1 mg kg-1), providing evidence
that this agent also slowed histamine clearance.

Figure 4.1: Histamine reuptake is inhibited by monoamine transporter inhibitors.
(A) Control hypothalamic histamine (blue) and 60 min post (i) GBR 12909 (ip,
15 mg kg-1), (ii) escitalopram (10 mg kg-1), (iii) sertraline (10 mg kg-1), (iv)
desipramine (15 mg kg-1), (v) citalopram (5 mg kg-1), and (vi) decynium-22 (0.1
mg kg-1) (green; n=5, each) Stimulation marked by grey box at 5-7 s. Error (±
standard error of the mean) is a shaded region around traces. Doses were reported
in prior work to create behavioral shifts or neurochemical changes.26, 30-34

Instead of only examining t1/2 here, we took a more sophisticated kinetic approach.
We used a previously developed mathematical model for histamine dynamics 28 to
investigate how physiological parameters could be adjusted to best capture curves for
escitalopram, citalopram, sertraline, and decynium-22. Model curves (dashed lines) are
compared to experimental curves (solid lines) in Figure 4.2. In all four cases, we found
that the major parameter change was a 50% reduction in the transport of extracellular
histamine back into the cell, consistent with the inhibition of histamine reuptake. To further
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narrow down which transporters are the largest contributor to histamine reuptake we used
the SERT Met172 mouse.

Figure 4.2: Modeled transporter data. Each panel shows the
experimental curves (solid lines) and model predictions (dashed
lines) both pre- and post-drug for the three different SSRIs and
decynium-22. The main difference between the pre-drug and
post-drug model curves was a 50% decrease in the reuptake of
histamine from the extracellular space into the histamine
varicosity. In the cases of escitalopram and decynium-22, the
uptake into glial cells was partially blocked, which is consistent
with the fact that the post-drug experimental curves are higher
and flatter in those two cases.

This mouse bears a single amino acid substitution (Ile172 is encoded in humans
and mice and here are converted to Met172) that impairs the binding of high affinity
antagonists, such as the SSRIs, without impacting serotonin uptake activity or in vivo
serotonin clearance (Fig. 4.3A).24-25, 35-36 In Figure 4.3, we show the effects of escitalopram
on changes in extracellular histamine and serotonin using this mouse. In Figure 4.3Bi and
ii, escitalopram administration inhibited histamine clearance in Met172 mice (t1/2: control:
3.65 ± 0.813 s; escitalopram: 5.35 ± 0.31 s; p=0.048) in a manner comparable to wild type
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mice. These data effectively rule out a role for SERT in histamine clearance or in the
actions of SSRIs to potentiate extracellular histamine levels but nonetheless show that
SSRIs inhibit histamine reuptake. In Figure 4.3Ci and ii, we monitored the effects of
escitalopram administration on extracellular hippocampal serotonin levels and confirmed
previous findings that escitalopram is ineffective at blocking serotonin clearance in Met172
mice.24 In wild type mice, escitalopram increased evoked hippocampal serotonin (Amp max:
29.19 ± 4.25 nM to 63.30 ± 5.33 nM; p= 0.008) and slowed extracellular clearance (t1/2:
1.50 ± 0.07 s; 7.98 ± 1.67 s; p=0.03) after 50 min.

Figure 4.3: Histamine reuptake is inhibited by monoamine transporter inhibitors.
(A) Cartoon schematic depicting SSRIs inability to bind to SERTs and prevent
serotonin reuptake in Met172 mouse. (B) Evoked hypothalamic histamine control
(blue) and 50 min post escitalopram (green, 10 mg kg-1) in (i) Met172 and (ii) WT
mice (n=4, each). (C) Evoked hippocampal serotonin control (grey) and 70+ min
post escitalopram (red, 10 mg kg-1) in (i) Met172 (n=5) and (ii) WT mice (n=4).
The grey and green bars represent the electrical stimulation from 5-7 s. Error (±
standard error of the mean) is a shaded region around traces.
4.4 Discussion
Commonly prescribed SSRIs, citalopram, escitalopram, and sertraline all inhibited
the reuptake of histamine following electrical stimulation (Figure 4.1). In addition to their
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high affinity for SERT, SSRIs do possess some off-target affinity for OCT.37-38 This is
particularly important to highlight in terms of antidepressant therapies. Serotonin is thought
to be decreased in the extracellular space in depressed patients and the goal of
antidepressants is to return serotonin to a healthy level. 39 In fact in the next chapter we
provide unequivocal evidence for this lowered serotonin level. Studies have documented
the comorbidity of inflammation and depression40-42 and elevated levels of
proinflammatory cytokines has spawned a new hypothesis on the underlying causes of
depression.43 However, pharmacological targeting of inflammatory biomarkers has yielded
inconsistent results.44-46 Histamine is a peripheral marker of inflammation and in Chapter
5 we show that histamine is also a maker of neuroinflammation. Given that during
inflammation (i.e. depression) brain histamine is increased and this histamine is at least
partially responsible for inhibiting serotonin levels, the compounds ostensibly prescribed
to alleviate depressive symptoms may in fact have detrimental effects through keeping
histamine present in the synapse and inhibiting the release of serotonin; antithetical to their
prescribed role. Antidepressants are prescribed to a substantial percentage of the population
and patients often take several weeks for symptom alleviation. 47 We highlight the critical
need for a comprehensive understanding of the molecular mechanisms of antidepressants
to improve clinical efficacy.
A histamine specific transporter has not yet been identified despite histamine
having reuptake kinetics similar to other rapidly cleared monoamines and histamine Nmethyltransferase being located intracellularly.13,

18-19

Indeed, in Samaranayake et al.

where we first described FSCV dual histamine-serotonin measurement, when
mathematically describing the responses, the models necessitated an active reuptake term
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to fit the histamine curves.17 Thus, we pharmacologically tested whether inhibition of other
monoamine transporters affected histamine reuptake. We inhibited SERTs (with three
different agents), DATs, and NETs and found that SERT and NET inhibition slowed the
clearance of histamine. Next we turned towards OCTs and PMATs. OCTs and PMATs are
low affinity transporters with the notable ability to non-selectively transport biogenic
amines.48-49 Gasser and colleagues recently showed that OCT and PMAT reuptake
histamine (and other monoamines) with varying affinities.22 Our results are in agreement
and show that OCT/PMAT inhibition via decynium-22 slowed the clearance of histamine
in vivo. However, these results do not definitively identify which transporter is responsible
for histamine reuptake because the different agents we administered have affinity for the
different monoamine transporters.20 Importantly, we show that histamine clearance was
inhibited by several compounds that all possess antidepressant activity in Figure 4.1
(sertraline, escitalopram, citalopram, desipramine, and decynium-22).50-51
To narrow down a histamine reuptake transporter, we utilized a transgenic mouse
model, the SERT Met172. SERT Met172 mice are a genetic knock-in strain which bear a
single amino acid substitution that renders their SERT insensitive to several SSRIs. 24, 35-36
Importantly, this model allows the SERT to remain intact and functioning, which is
arguably more physiologically relevant rather than removing SERT function entirely as in
a SERT knockout mouse.35, 52 Using this mouse, we observed that escitalopram no longer
antagonized serotonin reuptake (Figure 4.3C), yet still slowed histamine clearance,
strongly suggesting that a transporter other than SERT which escitalopram has affinity for 53
dictates

escitalopram-mediated

clearance.

Moreover,

a

NET-specific

tricyclic

antidepressant (desipramine) with little SERT activity also delayed histamine clearance.
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Given the ability of the OCT/PMAT inhibitor decynium-22 to inhibit evoked histamine
clearance, it seems likely that SERT-independent effects of SSRIs and the tricyclic
antidepressant may be mediated by these transporters. This is a reasonable assumption
given that OCTs are located most densely on glial cells that mediate the brain’s immune
reactions.54-55
It is important to remember the greater implications of this finding. During
depression and chronic stress, elevated levels of histamine are contributing to decreased
serotonin levels through H3 modulation. Antidepressants are prescribed with the intention
to raise serotonin in the extracellular space and increase receptor activation. However,
these very prescriptions may result in sustained histamine presence in the synapse
decreasing overall serotonin levels. Future work should be aimed at mitigating
antidepressant affinity for OCT and aimed at designing therapeutic targets with
neuromodulation in mind.
4.5 Conclusion
Histamine is an understudied neuromodulator, but its reuptake mechanism is not
fully elucidated. We pharmacologically inhibited serotonin transporters (SERT), dopamine
transporters (DAT), norepinephrine transporters (NET), organic cation transporters (OCT),
and plasma membrane monoamine transporters (PMAT) and found all agents that inhibited
histamine clearance exhibited antidepressant effects. We then used the transgenic mouse
model SERT Met172 to rule out SERT’s contribution to histamine reuptake in the brain.
Our data are in agreement with the conclusion that high efficiency, low affinity OCT are
responsible for the bulk of histamine reuptake. PMATs still remain to be studied more
extensively, but currently the only selective PMAT inhibitors are HIV protease inhibitors
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and present their own confounding factors. Antidepressants target the different monoamine
transporters to block reuptake in an effort to extend the amount of time that molecules
spend in the synapse. However, we have shown evidence that common SSRIs may have
off target effects on a chemical level that are opposite to their intended purpose.
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CHAPTER 5
HISTAMINE’S ROLES IN MEDIATING SEROTONIN DURING
NEUROINFLAMMATION1

1

Berger, SN., Hersey, M., Buchanan, AM., Ou, Y., Mena, S., Tavakoli, N., Reagan, L.,
Hashemi, P. Histamine’s roles in mediating serotonin during neuroinflammation. In
preparation. J. Neurosci. Res.
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5.0 Abstract
Depression is the leading cause of disability worldwide and current treatments are
variable with even the most efficacious selective serotonin reuptake inhibitors (SSRIs) only
benefitting ~30% of patients. The low efficacy is in part due to serotonin’s role in
depression remaining undefined. New research highlights a potential role for inflammation
in the low efficacy of antidepressants, further stressing the need to understand the complex
relationship between the brain, serotonin, antidepressants, and inflammation. Here we used
a chronic mild stress (CMS) paradigm, that is associated with depression phenotypes and
neuroinflammation. We analyzed the effect of CMS on the neurotransmission of histamine
and serotonin in the hypothalamus and hippocampus, respectively, with fast
electrochemical techniques. We found that CMS increased evoked histamine compared to
age matched control mice and decreased the extracellular levels of hippocampal serotonin.
Additionally, CMS induced inflammation impaired the ability of escitalopram, an SSRI, to
raise serotonin levels compared to control. Finally, we co-administered escitalopram with
a histamine synthesis inhibitor and found that alleviating histamine’s influence on
serotonin allows for escitalopram to increase serotonin in a similar fashion to non-stressed
control mice. These results suggest that histamine plays a crucial role in modulating
serotonin during inflammation and provides a novel therapeutic target as well as insight
into the neurochemical basis of depression.
5.1 Introduction
Depression is a debilitating disease that presents itself through a myriad of
symptoms and severities patient to patient.1-3 Rates of depression among the global
population have been steadily growing in recent decades, one reason being a decreased
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stigma surrounding mental health diagnoses. Health professionals warned about the
looming global mental health crisis associated with extensive isolation and feelings of
hopelessness during the unprecedented worldwide COVID-19.4-5 Despite increased
prevalence and reduced stigma around depression, treatments have remained stagnant with
only a few new therapies introduced in the last two decades.6
Traditional antidepressants focus on three main monoamine neurotransmitters that
underpin the monoamine hypothesis of depression – dopamine, norepinephrine, and
serotonin.7 The theory hypothesizes that one, two, or all of these monoamines are
dysregulated, and their concentrations are lowered in the synaptic area. 8 The majority of
antidepressants have focused on the serotonergic system, specifically aiming to block the
reuptake of serotonin through the serotonin transporter (SERT). This class of compounds,
selective serotonin reuptake inhibitors, has undergone thorough investigation since the
1970s balancing high affinity for SERT and minimal off-target effects.9 Despite decades
of research, treatments remain ineffective, with only ~30% of patients responding to their
first or second prescribed antidepressants and those who do respond typically experience
several weeks of delayed onset.10 Ultimately, treatment shortcomings stem from the fact
that there has not been a clearly identified chemical marker for depression that can be
‘corrected’ to restore a patient’s heath.
There is growing evidence that depression and inflammation, specifically
neuroinflammation, are comorbid but it is unclear which precipitates the other.11-12
Neuroinflammation is the CNS analogue of peripheral inflammation and is evidenced by
similar

biochemical

markers.13-14

What

remains

unclear

during

cases

of

neuroinflammation, is how histamine in the brain is reacting to the immune processes.
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Knowing that histamine is able to negatively modulate serotonin release in the brain via
H3Rs15 and common SSRIs inhibit the reuptake of histamine in the brain (Chapter 4), it is
critical to understand how histamine behaves in the brain during inflammation.
Interestingly, a strong link between inflammatory markers in serum and SSRI resistance
has been identified.16-17 Additionally, antidepressant treatment has been shown to reduce
inflammation and recent evidence suggests inhibiting proinflammatory cytokines can
alleviate depressive symptoms18-21 and increase SSRI efficacy.22-23 Studies have suggested
an important role for brain histamine in antidepressant treatment, therefore, we explored
this connection between histamine and serotonin during neuroinflammation.24-25
In this study, we utilize an established behavior paradigm (unpredictable chronic
mild stress; CMS) that is known to induce depression-like phenotypes and inflammation
in mice.

26-29

While we did not find strong significance in the depression phenotypes or

inflammation markers in these mice, using voltammetry we found that histamine was
significantly elevated. As such, CMS-treated mice displayed a decreased level of
extracellular serotonin and an impaired response to SSRI when compared to non-stressed
controls. We have shown that the CMS-treated mice response to SSRI can be restored when
histamine’s inhibitory action was eliminated by co-administering a histamine synthesis
blocker with the SSRI. These results highlight the importance of the histamine system and
inflammation in the underlying mechanisms of depression.
5.2 Materials and Methods
Chemicals and Reagents
Escitalopram oxalate (10 mg kg-1) (Sigma Aldrich, St. Louis, MO, USA) and αfluoromethylhistidine dihydrochloride (20 mg kg-1) (Toronto Research Chemicals Inc.,
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Toronoto, CAN) were individually dissolved in sterile saline (0.9% NaCl solution,
Hospira, Mountainside Medical Equipment, Marcy, NY, USA) and administered via
intraperitoneal (ip) injection at a volume of 5 mL kg-1 body weight. Urethane (Sigma
Aldrich, St. Louis, MO, USA) was dissolved in sterile saline at 25% w/v and administered
at 7 µL/g mouse body weight for surgical anesthesia.
Calibration solutions were prepared by dissolving serotonin hydrochloride (Sigma
Aldrich, St. Louis, MO, USA) in Tris buffer to produce solution concentration of 10, 25,
50, and 100 nM. Tris buffer consisted of 15 mM H2NC(CH2OH)2 HCl, 140 mM NaCl, 3.25
mM KCl, 1.2 mM CaCl2, 1.25 mM NaH2PO4 H2O, 1.2 mM MgCl2, and 2.0 mM Na2SO4
(Sigma Aldrich, St. Louis, MO, USA) in deionized water and pH adjusted to 7.4.
Electrode Fabrication
All electrodes are made in house. A single carbon fiber is aspirated into a
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige,
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is then
trimmed under light microscope to ~150 µm by scalpel. An electrical connection is forged
with the fiber through a stainless-steel connecting wire and silver epoxy. Finally, a thin
layer of Nafion (LQ-1105, Ion Power, New Castle, DE, USA) is electrodeposited onto the
fiber surface at 1 V for 30 s; the coated fiber is dried for 10 min at 70 °C.15, 30
Data Collection and Analysis
Fast-scan cyclic voltammetry and fast-scan controlled adsorption voltammetry
(FSCAV) were performed on anesthetized mice using a Dagan potentiostat (Dagan Corp.,
Minneapolis, MN, USA) and custom built hardware interfaced with PCIe 6341 & PCI 6221
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DAC/ADC cards (National Instruments, Austin, TX) and a Pine Research headstage (Pine
Research Instruments, Durham, NC, USA). WCCV 3.06 software (Knowmad
Technologies LLC, Tucson, AZ, USA) was used to control the hardware and perform data
analysis. For FSCV collection, the “Jackson” serotonin waveform31 was applied at 60 Hz
for 10 min, then at 10 Hz for 10 min prior to data collection or the histamine waveform (0.5 V to -0.7 V to +1.1 V to -0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at
10 Hz for min prior to data collection. Data were collected at 10 Hz. Neurotransmitter
release was evoked via biphasic stimulation applied through a linear constant current
stimulus isolator (NL800A Neurolog, Digitimer North America LLC, Fort Lauderdale, FL,
USA) with stimulations at 60 Hz, 360 µA, 2 ms in width, and 2 s in length.
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3
kHz low pass filter for histamine; 5kHz low pass filter for serotonin). For FSCV analysis,
the cyclic voltammogram (CV) was used to identify histamine and serotonin and the
current vs. time (IT) was extracted to visualize release and reuptake. Currents obtained
were converted to concentrations through previously generated calibration factors for both
histamine (2.825 µM nA-1) and serotonin (11 µM nA-1)15, 32 and hippocampal serotonin
(49.5 ± 10.2 nA/µM).30
For basal experiments, control evoked files were collected followed by the
methodology being switched to FSCAV. FSCAV was performed using a CMOS precision
analog switch, ADG419 (Analog Devices). For FSCAV collection, the serotonin waveform
was applied at 100 Hz for 2 s followed by a period of controlled adsorption where the
potential was held at 0.2 V for 10 s and then the serotonin waveform was reapplied at 100
Hz, as described in Abdalla et al.33 Thirty files (at one file min-1) were collected as control
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files. Following control files, an ip injection of saline was administered and 30 more files
of FSCAV were collected. Animals were then administered escitalopram (10 mg kg-1; ip)
and 60 files post-escitalopram were collected. The system was then switched back to
traditional FSCV and four post-basal stimulation files were collected. Electrodes were
removed from the animal and underwent post-calibration in which 10 files were collected
with the electrode in solutions of 10, 25, 50, and 100 nM serotonin.
For FSCV data, four IT curves were averaged for each animal to establish a control
signal. The average for each individual animal was then averaged throughout the group to
create an overall group average.
For FSCAV data, the first characteristic CV following waveform reapplication was
selected for quantification, and the peak occurring approximately between 0.4 and 0.85 V
was integrated to determine the charge (pC). Post-calibrations of each electrode, plotting
charge (pC) vs. [serotonin] (nM), were used to determine basal concentration.
Statistical Analyses
Exclusion criteria were based on outliers (via Grubbs test) and animals that did not
survive the experimental paradigm. To determine the t1/2, a code was custom written in
Excel to fit the reuptake component of the curve and calculate the time taken to reach half
the maximum amplitude. Standard error of the mean (SEM) was calculated using the
average response of each animal (n = # animals). Significance between two points was
determined by 2-tailed paired t-test and taken as p < 0.05. Two-way ANOVA was used to
determine significance between control max amplitude and the time course of drug max
amplitude. All error bars represent the standard error of the mean (SEM). Area under the
curve (AUC) was measured using Simpson’s rule of histamine release from time 0 s to the
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first intercept of the x axis; in the case of two peaks, only the first peak was analyzed. The
Shapiro-Wilk test was used to determine AUC data distribution. The Wilcoxon rank-sum
test was applied between control and CMS. Significance was taken as p<0.05.
Animals and Surgical Procedure
Animal procedures and protocols were in accordance with the regulations of the
Institutional Animal Care and Use Committee (IACUC) at the University of South
Carolina, accredited through the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC). Male and female C57BL/6J mice (Jackson
Laboratory, Bar Harbor, ME, USA) arrived at 6-7 weeks old group housed, with ad libitum
access to food and water, and were kept on a 12 h light/12 h dark cycle (lights off 0700;
light on 1900). An unpredictable chronic mild stress (CMS) paradigm was conducted over
a 16-week period and based on previously documented models.34-37 Two to three mild
stressors were performed a day. Stressors included: food or water deprivation,
confinement, cage tilt, soiled cage, light during dark cycle, bedding removal, novel object,
and handling. All stressors were stopped during behavior testing and 12 h leading up to
neurochemical studies.
Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed
induction of deep and sustained anesthesia from an ip injection of urethane. Mouse body
temperature was maintained using a thermal heating pad (Braintree Scientific, Braintree,
MA, USA). All surgical coordinates were taken in reference to bregma. 38 For serotonin
analysis, a Nafion coated CFM was lowered into the CA2 region of the hippocampus (AP:
-2.91, ML: +3.35, DV: -2.5 to -3.0) and a stimulating electrode (insulated stainless-steel,
diameter: 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial
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forebrain bundle (AP: -1.58, ML: +1.00, DV: -4.8). For histamine analysis, a Nafion coated
CFM was lowered into the posterior hypothalamus (AP: -2.45, ML: 0.50, DV: -5.45 to 5.55) and a stimulating electrode was placed into the medial forebrain bundle (AP: -1.07,
ML: +1.10, DV: -5.00). A pseudo-Ag/AgCl reference electrode, created by chloridizing a
polished silver wire in HCl (15 s in 1 M HCl at 5 V), was placed in the contralateral
hemisphere.
Behavioral Analyses
Following the CMS behavioral paradigm, mice underwent behavioral testing for
anxiety- and depressive-like phenotypes. Sucrose preference test (SPT) was conducted as
previously described.39 Briefly, mice were given access to water and 1% sucrose solution
for 24 h and the difference in consumption amounts was recorded. Elevated zero maze
(EZM) was conducted as previously described.40 Each mouse was placed into the closed
arm of the apparatus (Maze Engineers, Boston, MA, USA) and allowed to explore for 5
min. Time spent in the closed arm was measured as an indicator of anxiety-like behavior.
Tail suspension test (TST) was completed as previously described. 41 Mice were attached
via tape to a supported metal rod and a small plastic, flexible tube was placed on the tail to
limit climbing behavior within the apparatus (Maze Engineers, Boston, MA, USA) for the
duration of the 6 min test. Percent immobility was measured in the first two min (as pretest) and the remaining 4 min (test period) as an indicator of depressive-like behavior.
Forced swim test (FST) was conducted as previously described. 42 Briefly, mice were
individually placed in 4 L beakers filled with ~30 °C water for 5 min and the latency to
float and duration of floating (immobility) was recorded.
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Biochemical Analyses
BioPlex immunoassays (Bio-Rad Laboratories, Hercules, CA, USA) were used according
to manufacturer instructions to analyze cytokines in plasma at sacrifice.
5.3 Results
5.3.1 Behavioral and cytokine analyses
Following the stress paradigm, we analyzed behavioral tests for anxiety (elevated
zero maze) and depression through SPT, TST and FST. For the SPT (Figure 5.1B),
significantly less preference was only found in male mice after 12 h (control: 88.31 ±
0.92%; CMS: 83.33 ± 1.42%; p= 0.013). For the EZM (Figure 5.1C), CMS-treated mice
spent significantly more time in the closed arm of the maze than control mice (249.83 ±
2.76 s, 230.09 ± 3.79 s respectively; p < 0.001). For the FST, only male mice showed less
active behaviors after CMS (Con: 41.36 ± 8.05%; CMS: 66.14 ± 9.13%; p=0.035) (Figure
5.1D). There were no significant differences between control and CMS mice in the TST
despite a clear trend (65.64 ± 4.17 %, 70.50 ± 3.57 % respectively; p = 0.38) (Figure 5.1E).
While there is some significance in this data, in our hands CMS does not robustly (i.e. in
every animal) create depression-like phenotypes.
Similarly, we performed plasma cytokines analyses from these mice and found that
differences were weakly significant. There was no difference in peripheral cytokine
concentration between these two groups, however, when the ratios of proinflammatory
cytokines to anti-inflammatory cytokines were compared, for example with TNF- / IL-4
in females, significance was apparent (control: 15.18 ± 0.93 pg/mL; CMS: 19.30 ± 1.30
pg/mL; p = 0.016) (Figure 5.1F). CMS-treated mice also trended towards an increase in
IL-6/IL-4 ratios (p =0.21 and 0.24 in male and female mice) (Figure 5.1F). Overall,
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behavioral and plasma cytokine analysis yielded mild significance for the 16-week chronic
stress paradigm.

Figure 5.1: Behavioral and inflammatory changes following CMS
treatment. (A) A schematic is shown for the 16-week CMS
paradigm used as well as behavior, neurochemical, and
inflammation studies that followed. (B) Average sucrose preference
(sucrose water consumed - water consumed / total water consumed)
in the SPT for non-stress control (bue; n=40) and CMS (gray; n=39)
mice (t-test, p <0.001). (C) Average time spent in the closed sections
of the EZM is shown for control (blue; n=37) and CMS (gray; n=36)
mice. (D) Average percentage of time immobile in the FST for male
(blue) and female (light blue) control mice and male (gray) and
female (light gray) CMS mice. (E) Average percentage of time
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immobile in the TST is shown for control (blue) and CMS (gray)
mice. (F) Analysis of cytokine ratios (TNF-/IL-4 and IL-6/IL4
respectively). Significance was defined as p < 0.05 in a student’s ttest.

5.3.2 Hippocampal serotonin is decreased in CMS mice
In these mice we next measured evoked and ambient serotonin with fast-scan cyclic
voltammetry (FSCV) and fast-scan controlled adsorption voltammetry (FSCAV). We
developed these tools in our lab for minimally invasive, highly reproducible serotonin
measures on the neurotransmission temporal and spatial scale. There was no difference in
evoked serotonin in the hippocampus between control and CMS mice (Amp : Control:
max

19.02 ± 3.2 nM; CMS: 19.29 ± 3.71 nM; p = 0.804) or reuptake of serotonin (t : Control:
1/2

2.31 ± 0.27 s; CMS: 2.29 ± 0.26 s; p = 0.953) (Figure 2A-E). However, using FSCAV we
were able to show a robust difference in basal or ambient serotonin. In this region (Figure
2F-H), every single mouse that underwent the chronic stress paradigm had decreased
ambient serotonin (C : control: 63.17 ± 2.67 nM, CMS: 46.70 ± 0.72 nM; t-test, p <0.001),
max

despite weakly correlated behavioral and cytokine analysis.
5.3.3 Hypothalamic histamine is increased in CMS mice
Fast-scan cyclic voltammetry analysis of histamine was performed in the posterior
hypothalamus of the mice. In Figure 5.3A, a representative FSCV color plot is shown. The
[HA] vs time and [5HT] vs time is shown in Figure 5.3B for non-stressed control (blue)
and CMS-treated mice (green). There was no apparent change in the reuptake of histamine
between CMS and non-stressed control mice (t1/2: control: 2.5 ± 0.7 s; CMS: 3.2 ± 0.6 s;
p=0.23) The peak inhibition of serotonin following histamine release was increased in
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CMS mice, however this effect was not significant (Ampmax: control: 24.02 ± 6.30 nM;
CMS: 26.34 ± 4.32 nM; p=0.77).

Figure 5.2: Decreased extracellular serotonin predicts stress. (A,C)
Example 5HT color plots from control and CMS mice respectively. (B,D)
Example 5HT cyclic voltammograms from control and CMS mice
respectively. (E) Evoked hippocampal serotonin in control (blue) and
CMS (gray) mice. (F) An example of a basal serotonin color plot. (G) An
example of a basal serotonin cyclic voltammogram from which basal
serotonin was calculated using the equation shown (τ = Surface
Concentration, Q = Charge, n = Charge on the Molecule, F = Faraday
Constant, and A = Surface Area). (H) Average basal serotonin in control
(blue) and CMS (gray) mice is shown in a bar graph and individual
animals are denoted by circles. Error is shown as SEM and a student’s ttest was performed and significance defined as p < 0.05
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Figure 5.3 Chronic mild stress treatment elevates histamine. (A)
Representative color plot of evoked histamine and serotonin inhibition with
an inset cyclic voltammogram confirming the electrochemical identities of
histamine and serotonin. The blue bar represents electrical stimulation from
5 - 7 s. (B) Average CMS (green, n=5) and non-stressed control (blue, n=6)
evoked [histamine] and [serotonin] inhibition vs time profiles. Error (±
standard error of the mean) is shown as the shaded region around traces.
We hypothesized that the serotonin levels in CMS mice are low due to elevated
histamine in the hypothalamus Figure 5.3B, thus, we tested this notion and found in CMS
mice there is a non-significant increase in histamine release (control: 4.28 ± 0.51 M;
CMS: 5.64 ± 0.66 M; p=0.13) and a significant increase in area under the curve of
histamine release (AUC control: 14.51 ± 2.35 µM•s; CMS: 25.50 ± 2.80 µM•s; Wilcoxon
rank-sum test, p=0.02) (Figure C1).
The increased histamine explains the decreased ambient serotonin seen in Figure
5.2H. Therefore, we designed an experiment in which three groups of animals would
receive escitalopram under different treatments: non-stressed control (escitalopram; 10 mg
kg-1), CMS mice (escitalopram; 10 mg kg-1), and CMS mice co-administered escitalopram
(10 mg kg-1) and a histamine synthesis inhibitor (FMH; 20 mg kg-1) (Figure 5.4).
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Figure 5.4: Dual targeting of histamine and serotonin effects on
hippocampal serotonin in CMS-treated mice. Basal serotonin measurements
are shown for control mice given saline and then escitalopram (ip, 10 mg
kg-1, n=5, blue), CMS-treated mice given saline and then escitalopram (ip,
10 mg kg-1, n=5, grey), and CMS-treated mice given saline and then
escitalopram (ip, 10 mg kg-1) and FMH (ip, 20 mg kg-1, purple, n=5).
5.4 Discussion
5.4.1 Brain Serotonin is Lower in Response to Chronic Inflammation
The CMS treatment protocol is a model to induce depression-like phenotypes in
rodents that also results in associated neuroinflammation.26-29 Therefore, we used this
model to induce chronic inflammation in a cohort of mice to study the effects on brain
serotonin and histamine levels. While we found weak significance between this paradigm
and depression-like phenotypes and inflammation, using FSCV and FSCAV, developed in
our lab, to measure serotonin we found that CMS-treated mice exhibited a significantly
lower amount of ambient serotonin in the brain compared to control (Figure 5.4). This
phenomenon has been hypothesized and studied for some time.43-44 CMS has been said to
decrease brain serotonin levels45-47, a finding that has also been contradicted48 while acute
stress has been shown to increase serotonin.49-50 Importantly, CMS has also been associated
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with chronic inflammation.27, 51 Thus, agreement had not been reached in the community
about whether serotonin levels were actually lower during depression. Here for the first
time, we show that stress robustly decreases serotonin. Knowing histamine’s modulatory
control of serotonin, we next aimed to determine if histamine is altered in CMS-treated
mice.
5.4.2 Brain Histamine is Elevated during CMS Induced Neuroinflammation
Behaviorally depressed mice had higher levels of evoked histamine as analyzed by
fast scan cyclic voltammetry (Figure 5.3/C1). We contribute our small sample size to
unfortunate animal loss as behaviorally depressed mice are known to respond poorly to
anesthesia.52-54 Histamine has been shown to be a crucial signaling molecule for the
immune system55-56 and the connection between depression and altered immune system
functionality has been explored.57 Activated microglia and mast cells can regulate local
levels of histamine, which directly respond to immune reactions within the brain.58-62
Additionally, microglia and mast cell activation is thought to be linked to the induction of
anxiety and stress behaviors through inflammatory signaling.63-65 The role of histamine in
inflammatory communication in the brain has not yet been definitively determined, but
regulation appears to be complimentary in that histamine receptors can also affect cell
recruitment66-67 Here, we have shown that CMS-induced neuroinflammation increased
histamine and decreased serotonin levels in the brain. Previously, we showed that this
inverse modulation of histamine on serotonin was due to activation of H3 receptors present
on presynaptic serotonin terminals.15 We next sought to investigate the implication of this
relationship further.
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5.4.3 Dual pharmacological targeting of serotonin and histamine restores SSRI efficacy
during chronic inflammation
Our measurements of serotonin and histamine are in two distinctly different brain
regions, the hippocampus and the hypothalamus. We hypothesized that elevated
inflammation (thus elevated basal histamine levels) could mediate the lower extracellular
levels of serotonin observed in the hippocampus. We intended to remove the inhibitory
effect of histamine on H3 heteroreceptors on serotonin terminals to observe whether we
could return serotonin levels to pre-stress levels. Employing an antihistamine is enticing
but as covered in Chapter 3, those agents target post-synaptic H1 and H2, not H3 receptors,
and actually would result in sustained extracellular histamine. In fact, H 3R are not the ideal
pharmacological targets either as administering an agonist or antagonist would have
confounding effects (immepip or thioperamide; Chapter 3). Thus, we chose to globally
lower histamine levels by inhibiting the overall synthesis of histamine. We accomplish this
through α-fluoromethylhistidine (FMH), a suicide inhibitor of histidine decarboxylase
(sole enzymatic route of histamine synthesis). Studies have shown this compound
dramatically decreased both peripheral and central histamine.68-70 Co-administration of
escitalopram and FMH induced robust increases in ambient serotonin (Figure 5.4). We
postulated that dual targeting of histamine and serotonin could increase extracellular
serotonin and ameliorate the impaired SSRI-induced increases in serotonin seen in CMStreated mice. In CMS-treated mice, we observed ambient serotonin increased faster and to
a level comparable to control mice receiving escitalopram. Importantly, we suggest that
histamine may play a crucial role in serotonin dynamics as well as response to SSRI in
inflammatory states.
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5.5 Conclusion
Depression and inflammation are two inextricably linked phenomena that cause
debilitating effects in patients. We used an unpredictable chronic mild stress paradigm to
induce a depression-like phenotype and associated neuroinflammation in mice. We have
shown that serotonin levels are functionally lowered in chronically stressed mice and
confirm the notion that brain histamine levels are elevated during neuroinflammatory states
using in vivo fast-scan cyclic voltammetry. We postulated that elevated histamine is at least
partially responsible for decreased serotonin as we were able to restore escitalopram’s
ability to increase hippocampal serotonin in the absence of histaminergic control. Our
results highlight the importance of considering the histaminergic system and the role it
plays at the intersection of depression and inflammation.
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CHAPTER 6
AN IN VIVO ANALYSIS OF KETAMINE’S HISTAMINERGIC
MODULATION OF SEROTONIN IN THE POSTERIOR
HYPOTHALAMUS1

1

Berger, SN., Witt, CE., Baumberger Altirriba, BM., Hashemi, P. An in vivo analysis of
ketamine’s histaminergic modulation of serotonin in the posterior hypothalamus. In
preparation. Neurosci. Lett.
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6.0 Abstract
Ketamine is a dissociative anesthetic that has recently been highlighted for its
potential role as a rapid acting antidepressant in patients with major depressive and
treatment resistant depression. Despite the clinical rush to approve a treatment paradigm
utilizing ketamine, a large portion of ketamine’s antidepressant effects remain unknown.
We used fast voltammetric methods to investigate ketamine’s effects on monoamine
transmission in the hypothalamus and hippocampus of mice. We found ketamine caused a
robust decrease in electrically evoked histamine in the hypothalamus and increased
ambient serotonin levels in the hippocampus. We attributed these results to activation of
metabotropic glutamate receptors 2 & 3 and glutamatergic modulation of monoamine
transmission. Our data reveal new biochemical impacts of ketamine on the brain and will
aid in understanding ketamine’s antidepressant mechanisms.
6.1 Introduction
Ketamine is an important anesthetic, used primarily in veterinary medicine and
recognized as an essential medicine by the World Health Organization.1 Ketamine has
recently been proposed as a new sensational treatment for major depressive disorder
despite its storied history as a recreational drug of abuse. 2 While the clinical data on
ketamine treatment seems to show net positive effects on patients’ outcomes, benefits have
variable duration and require repeated injections.3-9 Exactly how ketamine exerts its effects
remains unknown. Ketamine is functionally different than ‘classical’ antidepressants in
that it doesn’t directly target one of the major monoaminergic systems eg. dopamine,
serotonin, or norepinephrine. Acting mainly as an N-methyl-D-aspartate (NMDA) receptor
antagonist, ketamine’s primary effects are on the glutamatergic and GABAergic systems.
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A substantial body of work has been dedicated to teasing apart which functional changes
are responsible for ketamine’s antidepressant effects. Metabolism of (R/S)-ketamine to
(2R,6R;2S,6S)-hydroxynorketamine appears to be essential for antidepressant effects.10
Interestingly, the S enantiomer is the more potent inhibitor of the NMDA receptors while
the R enantiomer metabolite appears significantly responsible for antidepressant effects
without the psychosis associated with the S enantiomer.11-12 These results, in conjunction
with the low clinical efficacy found in clinical trials, are curious considering the recent
Food and Drug Administration (FDA) approval of Johnson & Johnson’s Spravato, which
is an enantiomerically pure S-ketamine nasal spray.13
Much of the focus on understanding ketamine’s antidepressant effects has centered
around glutamate, GABA, and serotonin. Based on the known comorbidity of depression
and inflammation, in this work, we explored the role that histamine plays in this emerging
depression treatment. We previously observed that common selective serotonin reuptake
inhibitors (SSRIs) inhibit the reuptake of histamine from the synaptic cleft (Chapter 4)
and histamine levels are elevated in behaviorally depressed mice (Chapter 5). Histamine
remains an understudied molecule in the context of depression, therefore, our goal was to
expand the understanding of ketamine’s effects on the central nervous system by
monitoring how hypothalamic histamine responded to a sub-anesthetic dose of ketamine.
Additionally, we analyzed how the modulation of serotonin via histamine was altered
following ketamine exposure. We found that systemic administration of ketamine causes
rapid and sustained inhibition of hypothalamic histamine and attenuates histaminergic
inhibition of serotonin. As such, ketamine increases the ambient levels of serotonin in a
manner synonymous to standard SSRIs. Our results highlight critical mechanistic
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differences between rapid-acting and slow-acting antidepressants on key neurotransmitter
systems.
6.2 Methods and Materials
Chemicals and Reagents
Ketamine hydrochloride (Vet One, MWI Animal Health, Boise, ID, USA) and
escitalopram oxalate (Sigma Aldrich, St. Louis, MO, USA) were individually dissolved in
sterile saline (0.9% NaCl solution, Hospira, Mountainside Medical Equipment, Marcy,
NY, USA) and administered via intraperitoneal injection at 10 mg kg-1 and a volume of 5
mL kg-1 body weight. Urethane (Sigma Aldrich, St. Louis, MO, USA) was dissolved in
sterile saline at 25% w/v and administered at 7 µL/g mouse body weight for surgical
anesthesia.
Electrode Fabrication
All electrodes are made in house. A single carbon fiber is aspirated into a
borosilicate capillary (0.6 mm x 0.4 mm x 10 cm; OD x ID x L) (A-M Systems, Sequim
WA, USA) and sealed under gravity and heat by a vertical pipette puller (Narishige,
Amityville, NY, USA) to create two separate electrodes. The protruding fiber is then
trimmed under light microscope to ~150 µm by scalpel. An electrical connection is forged
with the fiber through a stainless-steel connecting wire and silver epoxy. Finally, a thin
layer of Nafion (LQ-1105, Ion Power, New Castle, DE, USA) is electrodeposited onto the
fiber surface at 1 V for 30 s; the coated fiber is dried for 10 min at 70 °C.14-16
Data Collection and Analysis
Fast-scan cyclic voltammetry was performed on anesthetized mice using a Dagan
potentiostat (Dagan Corp., Minneapolis, MN, USA), WCCV 3.06 software (Knowmad

109

Technologies LLC, Tucson, AZ, USA), and a Pine Research headstage (Pine Research
Instruments, Durham, NC, USA). The histamine waveform (-0.5 V to -0.7 V to +1.1 V to
-0.5 V at 600 V s-1) was applied at 60 Hz for 10 min, then at 10 Hz for min prior to data
collection. Data were collected at 10 Hz. Histamine was evoked via biphasic stimulation
applied through a linear constant current stimulus isolator (NL800A Neurolog, Digitimer
North America LLC, Fort Lauderdale, FL, USA) with stimulations at 60 Hz, 360 µA, 2 ms
in width, and 2 s in length.
Data were collected and filtered on WCCV software (zero phase, Butterworth, 3
kHz low pass filter). Four control evoked files, 10 min apart, were averaged for the control
evoked histamine signal after which ketamine was administered and files were collected at
0 min, 5 min, 10 min, and every 10 min thereafter until 100 min. Currents obtained were
converted to concentrations through previously generated calibration factors for both
histamine (2.825 µM nA-1) and serotonin (11 µM nA-1).15-16
For basal experiments, control evoked files were collected followed by the
methodology being switched to FSCAV. For FSCAV collection, the serotonin waveform
was applied at 100 Hz for 2 s followed by a period of controlled adsorption where the
potential was held at 0.2 V for 10 s and then the serotonin waveform was reapplied at 100
Hz, as described in Abdalla et al.17 Thirty files (at one file min-1) were collected as control
files. Following control files, an ip injection of saline was administered and 30 more files
of FSCAV were collected. Animals were then administered escitalopram (10 mg kg -1) ip
and 60 files post-drug were collected. The system was then switched back to traditional
FSCV and four post-basal stimulation files were collected. Electrodes were removed from
the animal and underwent post-calibration in which 10 files were collected with the
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electrode in solutions of 10, 25, 50, and 100 nM serotonin. For FSCAV data, the first
characteristic CV following waveform reapplication was selected for quantification, and
the peak occurring approximately between 0.4 and 0.85 V was integrated to determine the
charge (pC). Post-calibrations of each electrode, plotting charge (pC) vs. [serotonin] (nM),
were used to determine basal concentration.
Statistical Analyses
Average control response was generated from four current vs time traces per animal
and averaged to create an overall group average. Exclusion criteria were based on outliers
(via Grubbs test) and animals that did not survive the experimental paradigm. Standard
error of the mean (SEM) was calculated using the average response of each animal (n = #
animals). Significance between two points was determined by 2-tailed paired t-test and
taken as p < 0.05.
Animals and Surgical Procedure
Animal procedures and protocols were in accordance with the regulations of the
Institutional Animal Care and Use Committee (IACUC) at the University of South
Carolina, accredited through the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC). Male and female C57BL/6J mice (Jackson
Laboratory, Bar Harbor, ME, USA) 8-14 weeks of age weighing 20 to 29 g were used.
Stereotaxic surgery (David Kopf Instruments, Tujunga, CA, USA) followed
induction of deep and sustained anesthesia from an intraperitoneal injection of urethane
(below). Mouse body temperature was maintained using a thermal heating pad (Braintree
Scientific, Braintree, MA, USA). All surgical coordinates were taken in reference to
bregma.18 A Nafion coated CFM was lowered into the posterior hypothalamus (AP: -2.45,
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ML: 0.50, DV: -5.45 to -5.55) and a stimulating electrode (insulated stainless-steel,
diameter: 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was placed into the medial
forebrain bundle (AP: -1.07, ML: +1.10, DV: -5.00). A pseudo-Ag/AgCl reference
electrode, created by chloridizing a polished silver wire in HCl (15 s in 1 M HCl at 5 V),
was placed in the contralateral hemisphere.
6.3 Results
Administration of 10 mg kg-1 ketamine ip resulted in a significant decrease in the
overall amplitude of stimulated hypothalamic histamine (n=5; 2 male, 3 female; Ampmax:
control: 8.92 ± 1.80 µM; ketamine: 6.09 ± 1.61 µM; p = 0.005) while having no effect on
the clearance rate (t1/2: control: 4.1 ± 1.1 s; ketamine: 3.3 ± 0.8 s; p = 0.23) after 10 min
(Figure 6.1B).

Figure 6.1: Ketamine caused rapid inhibition of histamine release and
alleviates serotonin inhibition. (A) Representative color plot of stimulated
histamine and serotonin inhibition. Inset: CV showing oxidation peaks of
histamine and serotonin. (B) Top: evoked histamine control (blue, n=5) and
10 min following 10 mg kg-1 ketamine (green, n=5) (Amp : control: 8.92 ±
1.80 µM; ketamine: 6.09 ± 1.61 µM; p=0.005 paired t-test). Bottom:
[serotonin] vs time profiles for control (purple, n=5) and 10 min following
10 mg kg-1 ketamine (yellow) (Amp : control: 44.70 ± 7.91 nM; ketamine:
20.12 ± 4.88 nM; p=0.013 paired t-test). Error (± standard error of the mean)
is shown as a shaded region around traces.
max

max
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Ketamine administration had a rapid and sustained effect on suppressed histamine
release and alleviated serotonin inhibition throughout the duration (100 min) of data
collection (Figure 6.2A,B)

Figure 6.2: Ketamine caused prolonged suppression of histamine
release and serotonin inhibition. (A) Control evoked histamine
maximum amplitude (blue) and max amplitude for minutes 5, 10, 20,
to 100 min (green) following 10 mg kg-1 ketamine. (B) Control
serotonin inhibition minimum amplitude (purple) and inhibition
amplitude for minutes 5, 10, 20, to 100 min (yellow) following 10 mg
kg-1 ketamine. Error bars represent ± standard error of the mean.

There was no significant change in the reuptake curves (t1/2) of histamine control
(blue) or post-ketamine (green). Due to the inhibition profile of serotonin post-ketamine, it
was challenging to determine the reuptake kinetics associated with it. Qualitatively, it can
be seen that the overall amplitude of serotonin following ketamine is similar to the postinhibition (~25 s mark) amount in control signals.
We next investigated ketamine’s effect on ambient hippocampal serotonin. Control
serotonin levels were collected for 30 min prior to vehicle (saline; 30 to 60 min) injection.
Ketamine (blue; 0.66 nM/min) raised extracellular serotonin rapidly following ip
administration (60 to 120 min) in a similar fashion to escitalopram (orange; 0.482 ± 0.057
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nM/min), a classical antidepressant that inhibits the serotonin transporter. Saline vehicle
did not have an effect on serotonin for either compound (escitalopram, n=10 ; control:
63.68 ± 3.00 nM; saline: 63.53 ± 3.21 nM; p=0.68) (ketamine, n=2; control: 60.03 nM;
saline: 59.34 nM). Ketamine increased extracellular serotonin 60 min following injection
(control: 60.03 nM to 94.49 nM) similar to how escitalopram increased serotonin levels
(control: 63.68 ± 3.00 nM to 91.27 ± 4.64 nM).

Figure 6.3: Ketamine elevated ambient serotonin similar to escitalopram.
FSCAV data for mice receiving escitalopram (ip; 10 mg kg-1, orange, n=10)
or ketamine (ip; 10 mg kg-1, blue, n=2). Ambient serotonin concentration is
collected for 30 min, followed by 30 min of vehicle (saline), followed by
administration of ketamine (blue) or escitalopram (orange) for 60 min.
Ketamine (blue; 0.66 nM/min) raised extracellular serotonin rapidly
following ip administration (60 to 120 min) in a similar fashion to
escitalopram (orange; 0.482 ± 0.057 nM/min). Error bars have been omitted
for clarity.

6.4 Discussion
We have shown that administration of ketamine (10 mg kg-1; ip) caused rapid and
sustained inhibition of histamine release in the mouse posterior hypothalamus. Ketamine
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has not been shown to act directly on the histaminergic system, but most likely regulates
histamine through glutamatergic and GABAergic routes. GABAergic transmission is
inhibited by ketamine through NMDA receptor antagonism which leads to excess
glutamate release. The presence of histamine and GABA in tuberomammillary nucleus
neurons has been confirmed through immunohistochemistry19 and endogenous GABA has
been shown to modulate the release of histamine in the hypothalamus.20 Excess glutamate
release has been shown to influence the release of histamine and activate TMN neurons
which express both AMPA and NMDA receptors.21 NMDA receptor antagonists increased
the synthesis and turnover of histamine, which already occurs more frequently than other
monoamines in the brain.22-23 Infusions of glutamate in the anterior hypothalamus resulted
in a 150% increase in histamine with respect to baseline measured by microdialysis. 24
Okakura et al. noted that glutamate-evoked histamine release was completely blocked by
the NMDA receptor specific antagonist AP5, and AP5 alone reduced histamine release to
around 60% of basal levels.24 These results are in agreement with our data in that ketamine
caused a robust decrease in histamine release. Fell et al. reported that pretreatment with the
mGlu2 receptor agonist, LY379268, significantly attenuated histamine release and
concluded that hypothalamic histamine is modulated by glutamate through mGlu2
receptors.25-26 Glutamate is a highly potent endogenous agonist of mGlu2 receptors.27-28
The mGlu2 are located both pre- and post-synaptically and function as auto- and
heteroreceptors controlling the release of glutamate, GABA and other neurotransmitters. 29
The control of histamine release through glutamate activation of mGlu2/3 is a likely effect
from ketamine administration. Indeed, immunostaining has confirmed mGlu2 presence in
the premammillary nucleus30 and mGlu3 presence in TMN.30-31

115

The antidepressant effects of ketamine are thought to stem from synaptic plasticity
as a result of glutamate activated AMPA (alpha-amino-3-hydroxy-5-methyl-4isoxazoepropionic acid) receptors, increased BDNF (brain derived neurotrophic factor),
activation of mTOR (mammalian target of rapamycin), inhibition of glycogen synthase
kinase-3 or likely a combination of each.32-34 The importance of mTOR activation is
disputed as Li et al. reported inhibition of mTOR signaling blocked ketamine’s
antidepressant effects35 while Abdallah et al. recently reported that rapamycin pretreatment
(the inhibitor of mTOR) actually prolonged the antidepressant effects of ketamine for 2
weeks following initial ketamine treatment.36 The antagonism of NMDARs is not required
for antidepressant effects, but rather an increased level of cyclic adenosine monophosphate
(cAMP) that results in increased expression of BDNF.37-38 Activation of the AMPA
receptor is also thought to play an important role in the therapeutic effects of ketamine
through increased activation of mTOR, part of a signaling pathway that results in increased
BDNF that then increases synaptic plasticity.39 Antagonism of AMPA receptors
significantly blocked the beneficial effects of ketamine in rodents undergoing learned
helplessness, tail suspension, and forced swim tests (tests of depressive-like phenotypes).4041

The perisynaptically located metabotropic glutamate receptors 2&3 (mGlu2/mGlu3)

have also been highlighted for their role in the therapeutic effects of ketamine. 42-43 2R,6Rhydroxynorketamine functions as an antagonist of mGlu2/3 receptor.44 A combination of
ketamine and an mGlu2/3 receptor antagonist was shown to activate serotonin neurons in
the dorsal raphe nucleus.45
In addition to its anesthetic and antidepressant properties, ketamine bears analgesic
and anti-inflammatory effects. Ketamine’s ability to modulate the body’s immune response
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arose from observations of improved outcomes in critically ill patients 46 and experimental
septic shock.47 Ketamine has been shown to mitigate the inflammatory challenge of
lipopolysaccharide and decrease the production of pro-inflammatory cytokines during
immune response.48-51 The immunomodulatory role of ketamine was reviewed thoroughly
by De Kock and colleagues.52 In Chapter 5 we covered the influence of chronic mild stress
and neuroinflammation on brain histamine. In a similar chronic stress behavior model,
ketamine (10 mg kg-1) induced a rapid antidepressant effect and decreased expression of
hippocampal proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor
alpha (TNFα).53 Interestingly, ketamine’s inflammatory response may be dose dependent
as higher doses (50 mg kg-1 and above) have been shown to increase expression of
inflammatory proteins.54-55 Antidepressant benefits of ketamine involve sub-anesthetic
doses, therefore, the increased inflammatory signaling observed with high doses of
ketamine will generally not be expected.56 Overall, ketamine’s anti-inflammatory effects
function as a pretreatment to immune challenge rather than a response49 and ketamine has
no effect on cytokine production without an immune stimulus.52
We have shown that ketamine caused a robust and persistent decrease in evoked
histamine. Ketamine has been shown to elevated glutamate transmission while also
functioning as an anti-inflammatory agent. Previous reports are in agreement with our data
and concluded that ketamine, through glutamate activation inhibiting histamine release
through mGlu2/3 receptors and immunomodulatory abilities, could result in the decrease
of stimulated histamine. Most interestingly, the overall effect is on serotonin, in a manner
synonymous to SSRIs.
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6.5 Conclusion
In this report we investigated the effect of acute ketamine administration on
histamine and serotonin in vivo. In the posterior hypothalamus, we found that ketamine
caused a rapid and sustained decrease in histamine amplitude and lessened histamine’s
inhibition of serotonin 100 min following administration. Additionally, we confirmed the
increase in ambient serotonin by showing ketamine increased basal hippocampal serotonin
in a similar fashion to the SSRI escitalopram, despite its completely different mode of
action. The therapeutic effects of rapid acting antidepressants like ketamine are still being
uncovered. Our data provide new insights into the effects of rapid acting antidepressants
and how compounds targeting the glutamatergic system influence monoamine
neurotransmission.
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CHAPTER 7
CONCLUSIONS & PROSPECTS
The relationship of chemicals in the brain is delicate and dynamic. Histamine and
serotonin are two important bioamines that regulate many different processes within the
brain and body. Their actions and modulation are still being studied to fully understand the
impact histamine and serotonin have on brain disorders. However, analyzing the
underlying neurochemical changes of these two molecules has been challenging due to the
lack of robust analytical tools. This work continued previous Hashemi lab investigations
to uncover the intricate relationship histamine and serotonin have in the brain.
In this dissertation, I first reviewed the currently available tools for neurochemical
analysis and their respective advantages and drawbacks in Chapter 2. I then used FSCV to
investigate how CNS histamine responded to pharmacological challenge in male and
female mice in Chapter 3. I found that the histamine system is highly conserved between
male and female mice, owing to the brain’s homeostatic regulation. However, I determined
that female mice appear to have a higher level of immune regulation mediated by H 3
receptors. Next, I used a genetically modified mouse model to investigate the transport
mechanisms of histamine clearance in the brain and rule out SERT’s contribution to
histamine uptake in Chapter 4. With a better understanding of the male and female and
transport systems, I applied histamine FSCV to a model of chronic stress and chronic
inflammation (chronic mild stress behavioral paradigm) in Chapter 5. I showed that brain
histamine is elevated in this model of chronic stress/inflammation which is important in
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the context of histamine’s ability to inhibit serotonin release through H3 receptors. Finally,
I studied the effects of the newly approved antidepressant, ketamine in Chapter 6.
Ketamine’s antidepressant effects are rapid, relatively short lived requiring repeated
injections, and broadly not well understood. Unlike common antidepressants that target
traditional monoamines, ketamine targets the glutamatergic system and is thought to
modulate monoamines through glutamate and GABA. Knowing how histamine is changed
during depression and inflammation, and that in addition to its antidepressant effects,
ketamine has been shown to be anti-inflammatory, understanding how ketamine affected
histaminergic transmission provided novel information on its neurochemical mechanism.
This dissertation pushed our understanding of the co-modulation of histamine and
serotonin and how these two neurotransmitters respond to pharmaceutical targeting. Future
studies will have to further investigate the ability of female mice to regulate histamine
levels in the brain and the influence of cycling hormones on that regulation. Studies using
post-menopausal mice, ovariectomized mice, or mice given estrogen blocking compounds
should yield a clearer understanding of female H3 receptor control.
I applied histamine FSCV to a model of behaviorally induced chronic stress. In the
future, we plan to expand the application of histamine FSCV to other models of chronic
inflammation, neuroinflammation, and neurodegeneration. One such model is the
chemically induced Parkinson’s disease model MPTP (1-methyl-4-phenyl-1,2,3,6tetrahydropyridine) mouse. Additionally, due to the increased prevalence and risk posed
by environmental toxins in today’s world, we are in a unique position to study how
environmental exposures (eg. heavy metals, pesticides, polyaromatic hydrocarbons) affect
fundamental neurochemistry.
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Chapter 3 investigated a substantial amount of pharmacology of the histamine
system. We plan to collaborate with mathematicians to create a mathematical model
representing the physiological function of a histamine synapse. The model will encompass
both male and female aspects as well as the modulation of histamine and serotonin to create
a more complete picture than two separate systems. Ultimately, the product would be
applied to data obtained from neurodegenerative or inflammation animal models to
highlight key criteria (eg. release, reuptake, vesicular packaging) causing deficits.
Overall, this dissertation showcased the power of simultaneous, real-time
neurochemical measurements via FSCV. The continued advancement of our understanding
of the intricate relationships neurotransmitter systems have with one another will aid in the
development of novel strategies and therapies to manage the enormous burden psychiatric
disorders have on our populations.
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APPENDIX A
PERMISSION OBTAINED FROM ELSEVIER TO REPRINT THE
ARTICLE IN CHAPTER 2
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APPENDIX B
SUPPLEMENTAL FIGURES FOR CHAPTER 3

Figure B1: Representative images for estrous cycle determination. (A)
proestrus (B) estrus (C) metestrus (D) diestrus.
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Figure B2: Electrode placement in the posterior hypothalamus. Layered
brain slices and brain atlas images show the placement of CFM in
hypothalamus for single (green) and double (blue) histamine release
events.
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APPENDIX C
SUPPLEMENTAL MATERIAL FOR CHAPTER 5

Figure C1 CMS-treated mice have larger
stimulated histamine area under the curve. Violin
plot comparing the area under the curve of
stimulated histamine between non-stress control
mice and CMS-treated mice. (AUC control: 14.51
± 2.35 µM•s; CMS: 25.50 ± 2.80 µM•s; Wilcoxon
rank-sum test, p=0.02)
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